Phosphodiesterase 8A

ABSTRACT

The present invention provides novel human PDE8 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE8 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE8 polypeptides.

This is a Divisional of U.S. application Ser. No. 09/174,437, filed Oct. 16, 1998 now U.S. Pat. No. 6,133,007 and which is a continuation-in-part of U.S. patent application Ser. No. 08/951,648, filed Oct. 16, 1997, which is now U.S. Pat. No. 5,932,465.

FIELD OF THE INVENTION

The present invention relates generally to a family of phosphodiesterases designated PDE8A and uses thereof.

BACKGROUND OF THE INVENTION

Phosphodiesterases (PDEs) hydrolyze 3′,5′ cyclic nucleotides to their respective nucleoside 5′ monophosphates. The cyclic nucleotides cAMP and cGMP are synthesized by adenylyl and guanylyl cyclases, respectively, and serve as second messengers in a number of cellular signaling pathways. The duration and strength of the second messenger signal is a function of the rate of synthesis and the rate of hydrolysis of the cyclic nucleotide.

Multiple families of PDEs have been identified. The nomenclature system includes first a number that indicates the PDE family. To date, seven families (PDE1-7) are known which are classified by: (i) primary structure; (ii) substrate preference; (iii) response to different modulators; (iv) sensitivity to specific inhibitors; and (v) modes of regulation [Loughney and Ferguson, in Phosphodiesterase Inhibitors, Schudt, et al. (Eds.), Academic Press: New York, New York (1996) pp. 1-19]. The number indicating the family is followed by a capital letter, indicating a distinct gene, and the capital letter followed by a second number, indicating a specific splice variant or a specific transcript which utilizes a unique transcription initiation site.

The amino acid sequences of all mammalian PDEs identified to date include a highly conserved region of approximately 270 amino acids located in the carboxy terminal half of the protein [Charbonneau, et al., Proc. Natl. Acad Sci. (USA) 83:9308-9312 (1986)]. The conserved domain includes the catalytic site for cAMP and/or cGMP hydrolysis and two putative zinc binding sites as well as family specific determinants [Beavo, Physiol. Rev. 75:725-748 (1995); Francis, el al., J. Biol. Chem. 269:22477-22480 (1994)]. The amino terminal regions of the various PDEs are highly variable and include other family specific determinants such as: (i) calmodulin binding sites (PDE1); (ii) noncatalytic cyclic GMP binding sites (PDE2, PDE5, PDE6); (iii) membrane targeting sites (PDE4); (iv) hydrophobic membrane association sites (PDE3); and (v) phosphorylation sites for either the calmodulin-dependent kinase II (PDE1), the cAMP-dependent kinase (PDE1, PDE3, PDE4), or the cGMP dependent kinase (PDE5) [Beavo, Physiol. Rev. 75:725-748 (1995); Manganiello, et al., Arch. Biochem. Acta 322:1-13 (1995); Conti, et al., Physiol. Rev. 75:723-748 (1995)].

Members of the PDE1 family are activated by calcium-calmodulin. Three genes have been identified; PDE1A and PDE1B preferentially hydrolyze cGMP while PDE1C has been shown to exhibit a high affinity for both cAMP and cGMP. The PDE2 family is characterized as being specifically stimulated by cGMP [Loughney and Ferguson, supra]. Only one gene has been identified, PDE2A, the enzyme product of which is specifically inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA). Enzymes in the PDE3 family are specifically inhibited by cGMP. Two genes are known, PDE3A and PDE3B, both having high affinity for both cAMP and cGMP, although the V_(max) for cGMP hydrolysis is low enough that cGMP functions as a competitive inhibitor for cAMP hydrolysis. PDE3 enzymes are specifically inhibited by milinone and enoximone [Loughney and Ferguson, supra]. The PDE4 family effects cAMP hydrolysis and includes four genes, PDE4A, PDE4B, PDE4C, and PDE4D, each having multiple splice variants. Members of this family are specifically inhibited by the anti-depressant drug rolipram. Members of PDE5 family bind cGMP at non-catalytic sites and preferentially hydrolyze cGMP. Only one gene, PDE5A, has been identified. The photoreceptor PDE6 enzymes specifically hydrolyze cGMP [oughney and Ferguson, supra]. Genes include PDE6A and PDE6B (the protein products of which dimerize and bind two copies of a smaller γ inhibitory subunit to form rod PDE), in addition to PDE6C which associates with three smaller proteins to form cone PDE. The PDE7 family effects cAMP hydrolysis but, in contrast to the PDE4 family, is not inhibited by rolipram [Loughney and Ferguson, supra]. Only one gene, PDE7A, has been identified.

1. Given the importance of cAMP and cGMP in intracellular second messenger signaling, there thus exists an ongoing need in the art to identify addition PDE species. Identification of heretofore unknown families of PDEs, and genes and splice variants thereof, will provide additional pharmacological approaches to treating conditions in which cyclic nucleotide pathways are aberrant as well as conditions in which modulation of intracellular cAMP and/or cGMP levels in certain cell types is desirable.

SUMMARY OF THE INVENTION

In brief, the present invention provides polypeptides and underlying polynucleotides for a novel PDE family designated PDE8. The invention includes both naturally occurring and non-naturally occurring PDE8 polynucleotides and polypeptide products thereof Naturally occurring PDE8 products include distinct gene and polypeptide species within the PDE8 family (i.e., PDE8A); these species include those which are expressed within cells of the same animal and well as corresponding species homologs expressed in cells of other animals. Within each PDE8 species, the invention further provides splice variants encoded by the same polynucleotide but which arise from distinct mRNA transcripts (i.e., PDE8A1 and PDE8A2). Non-naturally occurring PDE8 products include variants of the naturally occurring products such as analogs (i.e., wherein one or more amino acids are added, substituted, or deleted) and those PDE8 products which include covalent modifications (i.e., fusion proteins, glycosylation variants, Met⁻¹PDE8s, Met⁻²-Lys⁻¹-PDE8s, Gly⁻¹PDE8s and the like). The PDE8 family is distinguished from previously known PDE families in exhibiting high affinity for hydrolysis of both cAMP and cGMP but relatively low sensitivity to enzyme inhibitors specific for other PDE families. In a preferred embodiment, the invention provides a polynucleotide comprising the sequence set forth in SEQ ID NO: 1. The invention also embraces polynucleotides encoding the amino acid sequence set out in SEQ ID NO: 2. A presently preferred polypeptide of the invention comprises the amino acid sequence set out in SEQ ID NO: 2. The invention provides two splice variant cDNAs which give rise to two polypeptides designated PDE8A1 and PDE8A2. PDE8A1 and PDE8A2 polypeptides, and the polynucleotides encoding the polypeptides, are discussed herein as representative of the PDE8 enzyme family embraced by the invention.

The present invention provides novel purified and isolated polynucleotides (e.g., DNA sequences and RNA transcripts, both sense and complementary antisense strands, including splice variants thereof) encoding the human PDE8s. DNA sequences of the invention include genomic and cDNA sequences as well as wholly or partially chemically synthesized DNA sequences. “Synthesized,” as used herein and is understood in the art, refers to purely chemical, as opposed to enzymatic, methods for producing polynucleotides. “Wholly” synthesized DNA sequences are therefore produced entirely by chemical means, and “partially” synthesized DNAs embrace those wherein only portions of the resulting DNA were produced by chemical means. A preferred DNA sequence encoding a human PDE8 polypeptide is set out in SEQ ID NO: 1. Also preferred are polynucleotides encoding the PBE8 polypeptide of SEQ ID NO: 2 and the PDE8A1 and PDE8A2 splice variant polypeptides set out in SEQ ID NOs: 6 and 4, respectively. Preferred polynucleotides encoding PDE8A1 and PDE8A2 are set out in SEQ ID NOs: 5 and 3, respectively. The invention further embraces species, preferably mammalian, homologs of the human PDE8 DNA.

The invention also embraces DNA sequences encoding PDE8 species which hybridize under moderately stringent conditions to the non-coding strands, or complements, of the polynucleotides in SEQ ID NOs: 1, 3 and 5. DNA sequences encoding PDE8A polypeptides which would hybridize thereto but for the redundancy of the genetic code are contemplated by the invention. Exemplary moderate hybridization conditions are as follows: hybridization at 65° C. in 3×SSC, 0.1% sarkosyl, and 20 mM sodium phosphate, pH 6.8, and washing at 65° C. in 2×SSC with 0.1% SDS. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described Ausebel, et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook, et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y. (1989), pp. 9.47 to 9.51.

Autonomously replicating recombinant expression constructions such as plasmid and viral DNA vectors incorporating PDE8 sequences are also provided. Expression constructs wherein PDE8-encoding polynucleotides are operatively linked to an endogenous or exogenous expression control DNA sequence and a transcription terminator are also provided.

According to another aspect of the invention, host cells are provided, including procaryotic and eukaryotic cells, either stably or transiently transformed with DNA sequences of the invention in a manner which permits expression of PDE8 polypeptides of the invention. Host cells of the invention are a valuable source of immunogen for development of antibodies specifically immunoreactive with PDE8. Host cells of the invention are also conspicuously useful in methods for large scale production of PDE8 polypeptides wherein the cells are grown in a suitable culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells are grown by, for example, immunoaffinity purification.

Knowledge of PDE8 DNA sequences allows for modification of cells to permit, or increase, expression of endogenous PDE8. Cells can be modified (e.g., by homologous recombination) to provide increased PDE8 expression by replacing, in whole or in part, the naturally occurring PDE8 promoter with all or part of a heterologous promoter so that the cells express PDE8 at higher levels. The heterologous promoter is inserted in such a manner that it is operatively-linked to PDE8 encoding sequences. See, for example, PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808, and PCT International Publication No. 91/09955. The invention also contemplates that, in addition to heterologous promoter DNA, amplifiable marker DNA (e.g., ada, dhfr, and the multifunctional CAD gene which encodes carbamyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase) and/or intron DNA may be inserted along with the heterologous promoter DNA. If linked to the PDE8 coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of the PDE8 coding sequences in the cells.

The DNA sequence information provided by the present invention also makes possible the development through, e.g homologous recombination or “knock-out” strategies [Capecchi, Science 244:1288-1292 (1989)], of animals that fail to express functional PDE8 or that express a variant of PDE8. Such animals are useful as models for studying the in vivo activities of PDE8 and modulators of PDE8.

The invention also provides purified and isolated mammalian PDE8 polypeptides. Presently preferred PDE8A polypeptides are set out in SEQ ID NOs: 4 and 6. Most preferred is a PDE8 polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2. PDE8 polypeptides of the invention may be isolated from natural cell sources or may be chemically synthesized, but are preferably produced by recombinant procedures involving host cells of the invention. Use of mammalian host cells is expected to provide for such post-translational modifications (e.g., glycosylation, truncation, lipidation, and phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the invention. PDE8 products of the invention may be fall length polypeptides, biologically active fragments, or variants thereof which retain specific PDE8 biological activity. Variants may comprise PDE8 polypeptide analogs wherein one or more of the specified (i.e., naturally encoded) amino acids is deleted or replaced or wherein one or more non-specified amino acids are added: (1) without loss of one or more of the biological activities or immunological characteristics specific for PDE8; or (2) with specific disablement of a particular biological activity of PDE8.

Variant products of the invention include mature PDE8A products, i.e., PDE8 products wherein leader or signal sequences are removed, having additional amino terminal residues. PDE8 products having an additional methionine residue at position -1 (Met⁻¹-PDE8) are contemplated, as are PDE8 products having additional methionine and lysine residues at positions -2 and -1 (Met⁻²-Lys⁻¹-PDE8). Variants of these types are particularly useful for recombinant protein production in bacterial cell types.

The invention also embraces PDE8 variants having additional amino acid residues which result from use of specific expression systems. For example, use of commercially available vectors that express a desired polypeptide such as a glutathione-S-transferase (GST) fusion product provide the desired polypeptide having an additional glycine residue at position -1 as a result of cleavage of the GST component from the desired polypeptide. Variants which result from expression in other vector systems are also contemplated.

The invention further embraces PDE8 products modified to include one or more water soluble polymer attachments. Particularly preferred are PDE8 products covalently modified with polyethylene glycol (PEG) subunits. Water soluble polymers may be bonded at specific positions, for example at the amino terminus of the PDE8 products, or randomly attached to one or more side chains of the polypeptide.

Also comprehended by the present invention are antibodies (e.g., monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, CDR-grafted antibodies and the like) and other binding proteins specific for PDE8 products or fragments thereof. Specific binding proteins can be developed using isolated or recombinant PDE8 products, PDE8 variants, or cells expressing such products. Binding proteins are useful for purifying PDE8 products and detection or quantification of PDE8 products in fluid and tissue samples using known immunological procedures. Binding proteins are also manifestly useful in modulating (i.e., blocking, inhibiting or stimulating) biological activities of PDE8, especially those activities involved in signal transduction. Anti-idiotypic antibodies specific for anti-PDE8 antibodies are also contemplated.

The scientific value of the information contributed through the disclosures of DNA and amino acid sequences of the present invention is manifest. As one series of examples, knowledge of the sequence of a cDNA for PDE8A makes possible through use of Southern hybridization or polymerase chain reaction (PCR) the identification of genomic DNA sequences encoding PDE8 and PDE8 expression control regulatory sequences such as promoters, operators, enhancers, repressors, and the like. DNA/DNA hybridization procedures carried out with DNA sequences of the invention under moderately to highly stringent conditions are likewise expected to allow the isolation of DNAs encoding allelic variants of PDE8A; allelic variants are known in the art to include structurally related proteins sharing one or more of the biochemical and/or immunological properties specific to PDE8A. Similarly, non-human species genes encoding proteins homologous to PDE8A can also be identified by Southern and/or PCR analysis. As an alternative, complementation studies can be useful for identifying other human PDE8 products as well as non-human proteins, and DNAs encoding the proteins, sharing one or more biological properties of PDE8A.

Polynucleotides of the invention are also useful in hybridization assays to detect the capacity of cells to express PDE8. Polynucleotides of the invention may also be the basis for diagnostic methods useful for identifying a genetic alteration(s) in a PDE8 locus that underlies a disease state or states.

Also made available by the invention are anti-sense polynucleotides which recognize and hybridize to polynucleotides encoding PDE8. Full length and fragment anti-sense polynucleotides are provided. Anti-sense polynucleotides are particularly relevant to regulating expression of PDE8 by those cells expressing PDE8 mRNA.

The DNA and amino acid sequence information provided by the present invention also makes possible the systematic analysis of the structure and function of PDE8s. DNA and amino acid sequence information for PDE8 also permits identification of molecules with which PDE8A will interact. Agents that modulate (i.e., increase, decrease, or block) PDE8 activity may be identified by incubating a putative modulator with PDE8 and determining the effect of the putative modulator on PDE8 phosphodiesterase activity. The selectivity of a compound that modulates the activity of the PDE8 can be evaluated by comparing its activity on the PDE8 to its activity on other PDE enzymes. Cell based methods, such as di-hybrid assays and split hybrid assays, as well as in vitro methods, including assays wherein a polypeptide or its binding partner are immobilized, and solution assays are contemplated by the invention.

Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to the PDE8 or PDE8 nucleic acid, oligonucleotides which specifically bind to the PDE8 or PDE8 nucleic acid, and other non-peptide compounds (e.g., isolated or synthetic organic molecules) which specifically react with PDE8 or PDE8-encoding nucleic acid. Mutant forms of PDE8 which affect the enzymatic activity or cellular localization of the wild-type PDE8 are also contemplated by the invention. Presently preferred targets for the development of selective modulators include, for example: (1) regions of the PDE8 which contact other proteins and/or localize the PDE8 within a cell, (2) regions of the PDE8 which bind substrate, (3) allosteric cyclic nucleotide-binding site(s) of PDE8, (4) phosphorylation site(s) of PDE8 and (5) regions of the PDE8 which are involved in multimerization of PDE8 subunits. Modulators of PDE8 activity may be therapeutically useful in treatment of a wide range of diseases and physiological conditions in which PDE activity is known to be involved.

The invention further contemplates small molecule modulators of PDE8A enzyme activity. There are at least three different types of libraries used for the identification of small molecule modulators. These include: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries comprised of random peptides, oligonucleotides or organic molecules.

Chemical libraries consist of structural analogs of known compounds or compounds that are identified as “hits” or “leads” via natural product screening. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms which are used to create mixtures for screening by: (1) fermentation and extraction of broths from soil, plant or marine microorganisms or (2) extraction of plants or marine organisms. Combinatorial libraries are composed of large numbers of peptides, oligonucleotides or organic compounds as a mixture. They are relatively easy to prepare by traditional automated synthesis methods, PCR, cloning or proprietary synthetic methods. Of particular interest are peptide and oligonucleotide combinatorial libraries. Still other libraries of interest include peptide, protein, peptidomimetic, multiparallel synthetic collection, recombinatorial, and polypeptide libraries. For a review of combinatorial chemistry and libraries created therefrom, see Myers, Curr. Opion. Biotechnol. 8:701-707 (1997).

Identification of modulators through use of the various libraries described herein permits modification of the candidate “hit” (or “lead”) to optimize the capacity of the “hit” to modulate activity.

The invention further provides methods to identify a specific binding partner compound of a PDE8A polypeptide of the invention comprising the steps of: a) contacting the PDE8A polypeptide with a compound under conditions which permit binding between the compound and the PDE8A polypeptide; b) detecting binding of the compound to the PDE8A polypeptide; and c) identifying the compound as a specific binding partner of the PDE8A polypeptide. Binding partner identified in the methods of the invention preferably modulate PDE8A enzyme activity, either through inhibition or activation, or enhancement, of the enzyme.

The invention also provides methods to identify a specific binding partner compound of a PDE8A polynucleotide of the invention comprising the steps of: a) contacting the PDE8A polynucleotide with a compound under conditions which permit binding between the compound and the PDE8A polynucleotide; b) detecting binding of the compound to the PDE8A polynucleotide; and c) identifying the compound as a specific binding partner of the PDE8A polynucleotide. The binding partner of the PDE8A polynucleotide preferably modulates expression of the PDE8A polypeptide encoded by the PDE8A polynucleotide, either through inhibiting expression or enhancing expression.

The invention also provides compounds identified by a method of the invention, as well as compositions comprising a compound identified and a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is illustrated by the following examples which relate to the isolation of polynucleotides encoding PDE8 polypeptides as well as expression and charactelization of the encoded polypeptides. Example 1 describes methods for searching expressed sequence tag (EST) databases in order to identify probes potentially useful for isolating DNAs of the invention. Example 2 relates to identification of PDE8A-encoding polynucleotides. Example 3 addresses sequence analysis of the isolated polynucleotides. Example 4 describes analysis of polypeptides encoded by the PDE8A polynucleotides. Example 5 addresses expression of recombinant PDE8A polypeptides. Example 6 relates to Northern analysis of PDE8A expression. Example 7 describes chromosome mapping of the gene encoding PDE8A. Example 8 describes confirmation that PDE8A1 and PDE8A2 are splice variants. Example 9 addresses expression and characterization of recombinant PDE8A. Example 10 details production of anti-PDE8A monoclonal antibodies. Example 11 describes an analysis of PDE8A expression by in situ hybridization.

EXAMPLE 1 Identification of an EST Related to a Human PDE

Using the sequences of known human, 3′,5′ cyclic nucleotide phosphodiesterases, a search of the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database was undertaken in order to identify cDNA fragments that could potentially be useful for the identification of novel phosphodiesterase (PDE) genes. This database contains DNA sequences representing one or both ends of cDNAs collected from a variety of tissue sources. A single sequencing run is performed on one or both ends of the cDNA and the quality of the DNA sequence varies tremendously. At the time the PDE searches were performed, the EST sequence database contained more than 600,000 cDNA sequences from a variety of organisms.

The search for novel PDE sequences included three steps. First the BLASTN program available through NCBI was used to identify DNA sequences in the EST sequence database with homology to cDNA sequences encoding known human PDEs. The program compares a nucleotide query sequence against a nucleotide sequence database. The cDNA sequences of the fifteen known human PDEs were submitted and fifteen BLASTN searches were performed; the query PDE sequences included PDE1A3 [Loughney, et al., J. Biol. Chem. 271:796-806 (1996)], PDE1B1 [Yu, et al., Cell Signaling, in press (1997)], PDE1C2 [Loughney, el al., J. Biol. Chem. 271:796-806 (1996)], PDE2A3 [Rosman, et al., Gene 191:89-95 (1997)], PDE3A [Meacci, et al., Proc. Natl. Acad. Sci. (USA) 89:3721-3725 (1992)], PDE3B [Miki et al., Genomics 36:476485 (1996)], PDE4A5 [Bolger, et al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE4B2 [Bolger, et al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE4C [Bolger, et al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE4D1 and PDE4D3 [Bolger, el al., Mol. Cell. Biol. 13:6558-6571 (1993)], PDE5A, PDE6A [Pittler, et al., Genomics 6:272-283 (1990)], PDE6B [Collins, et al., Genomics 13:698-704 (1992)], PDE6C [Piriev, et al., Genomics 28:429-435 (1995), and PDE7A1 [Michaeli, et al., J. Biol. Chem. 17:12925-12932 (1993)]. The BLASTN results were examined and EST sequences that were judged as corresponding to each of the fifteen known PDE cDNAs were identified and collected into a table. The PDE6A and PDE6B sequences used as queries were truncated at 3′ end (removing a portion of the 3′ untranslated region) due to the presence of repetitive elements in the 3′ untranslated region of the cDNAs.

Secondly, the NCBI TBLASTN program was used to examine the homology between the protein sequence of the fifteen known human PDEs (as above) and the six different possible proteins encoded by each of the EST DNA sequences. In this search, the EST sequences are translated in six frames and the amino acid sequences generated are compared to the query PDE amino acid sequences. Sequences identified as homologous at the amino acid level were examined and any EST sequences positively identified as corresponding to a known PDE during the BLASTN search described above were discarded.

The third step of the search involved analyzing the sequences that were not known PDEs. These amino acid sequences were homologous to a known PDE but were not identified as one of the 15 known PDE genes during the BLASTN searches.

The BLAST searches identified an EST sequence (designated WO4835) from a human fetal lung cDNA library as encoding an amino acid sequence having homology to the catalytic region of PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE5A, rod alpha PDE6A, rod beta PDE6B, cone alpha PDE6C, and PDE7A The database sequence for WO4835 is set out in SEQ ID NO: 7. Results from the database analysis as discussed below are exemplified using the PDE4D sequence.

WO4835 cDNA was obtained from American Type Culture Collection (Rockville, Md.) which maintains and makes publicly available deposits of ESTs identified and sequenced by I.M.A.G.E., Lawrence Livermore National Laboratory, Livermore, Calif.). The WO4835 DNA was sequenced upon receipt to confirm its identity and determined to be consistent with SEQ ID NO: 7.

The amino acid sequence encoded by the −1 reading frame of EST sequence WO4835 was recognized by all of the PDE query cDNA sequences except PDE1A, 1B and 1C. Using the TBLASTN results with PDE4D3 as an example, two regions of similarity were detected. The first region showed 15/37 exact matches or 40% identity (19/37 similar amino acids) and included the HD(X)₂HXG(X)₁₃A (SEQ ID NO: 8) motif found in all of the query sequences. [Charboneau, Mol. Pharmacol. Cell Regul. 2:267-298 (1990)]. The second region showed 9/20 exact matches or 45% identity and included the YHNxxHA motif found in most of the query sequences. BLASTN analysis of the WO4835 sequence revealed that it was unique in that it was not identical to any other human DNA sequences in the Genbank database. The EST database entry for WO4835 identified the sequence as being similar to PIR:A48719, the bovine cGMP binding, cGMP hydrolyzing PDE5A1 sequence. Comparison of the protein sequence of WO4835 frame −1 to the bovine PDE5A1 sequence revealed 58/153 matches for an overall identify of 38%. Within this region were small regions of greater homology; one region showed a 12/14 identical amino acids. Given the unique nature of the WO4835 sequence, its relatively low homology to bovine PDE5A1, and the presence of the amino acid motifs found in most other known human PDE amino acid sequences, WO4835 represents a novel human PDE cDNA.

EXAMPLE 2 Isolation of Putative PDE cDNA

WO4835 cDNA insert was digested from the pT7T3D vector into two fragments with the restriction enzymes EcoRI and HindIII and the two fragments were purified using two sequential low melting agarose gels. Both fragments were used as probes to screen cDNA libraries derived from human heart (Stratagene, La Jolla, Calif.), and human fetal brain (Stratagene) using procedures routinely practiced in the art. Approximately 5×10⁵ phage from each library were screened. Hybridization was carried out overnight in buffer containing 3×SSC, 0.1% Sarkosyl, 20 mM sodium phosphate, pH 6.8, 10×Denhardt's solution, and 50 μg/ml salmon sperm DNA at 65° C. The filters were washed at 65° C. in buffer containing 2×SSC and 0.1% SDS prior to autoradiography.

Nine clones from the fetal brain cDNA library and two from the heart cDNA library hybridized to the WO4835 probe. Partial sequencing and mapping led to the selection of one clone from the fetal brain library designated FB66a for further characterization.

A second screening of approximately 7.5×10⁵ phage from the fetal brain cDNA library under conditions used in the first screening using the 1.3 kb EcoRI/HindIII fragment from the 5′ portion of WO4835 yielded nineteen additional cDNA clones. Six of these cDNAs also hybridized to a HindIII/KpnI fragment of WO4835 which includes a 256 nucleotide region at the 5′ end of WO4835. Partial sequencing and mapping of five of the clones led to the selection of a second clone designated FB85c-2 for further analysis.

EXAMPLE 3 DNA Sequence Analysis of FB66a and FB85c-2

The DNA sequence of FB66a was determined for both strands using DNA oligonucleotide primers set out below in SEQ ID NOs: 9 to 31 and a Perkin Elmer Applied Biosystems Division 373A DNA Sequencer according to the maunfacturer's suggested protocol. The amount of PCR product used as template was calculated based on the size of the PCR product and was sequenced using ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit with ApliTaq DNA Polyymerase, FS (Perkin Elmer, Foster City, Calif.) and asymrnetric PCR. The reaction product was purified on a AGCT spin column (Advanced Genetic Technologies Corp., Gaithersburg, Md.) and dried. Loading buffer was added to each purified sample and the mixture heated at 90° C. for two minutes. The solution was transferred to ice until being loaded onto a 4% polyacrylamide gel. Data was automatically collected once the Data Collection program was initiated and was automatically analyzed and read by the Sequence Analysis program. All editing was performed manually and the resulting sequences were aligned where the consensus sequence was determined.

M13Rev.1 GGAAACAGCTATGACCATG SEQ ID NO: 9 W48A2 ACTCTCCAAGGAAATACAG SEQ ID NO: 10 W48A9 CTGTCTCTGCACTAACAC SEQ ID NO: 11 W48A4 TTGGCAAGGCCTCTGCAT SEQ ID NO: 12 W48S1 CCTCTATGAACTGAGCAG SEQ ID NO: 13 W48A1 GAAGGCACTGCCACTGAT SEQ ID NO: 14 W48S6 TCGAGCTGTATCGGCACT SEQ ID NO: 15 W48A5 AGCGTGTGATTGTTCTGAA SEQ ID NO: 16 W48S7 TGCTGGCCAAGTAGCAAG SEQ ID NO: 17 W48A6 AAGGTCACAGGCAGTCAT SEQ ID NO: 18 W48S2 GAAGAGTGGCAAGGTCTC SEQ ID NO: 19 W48S3 TCATGACCTGGACCACCAG SEQ ID NO: 20 W48A8 CCTTCTTGAAGAGGTTTGC SEQ ID NO: 21 W48S4 ATGACTGCCTGTGACCTT SEQ ID NO: 22 W48S5 CTGCTATACAACCCTTACC SEQ ID NO: 23 W48S8 GCTAATATTGCTGAGGCC SEQ ID NO: 24 W48A7 TAAGTGAGAGGTGACTGC SEQ ID NO: 25 W48S9 CCTAAAGGGCTGAGATCA SEQ ID NO: 26 W48S10 CGCAGTCACCTCTCACTT SEQ ID NO: 27 M13 TGTAAAACGACGGCCAGT SEQ ID NO: 28 W48A11 ACAAAACGCCTATGGTGG SEQ ID NO: 29 W48A10 TTGATCTCAGCCCTTTAGC SEQ ID NO: 30 W48S11 TCATGTGGCAGGAAACTG SEQ ID NO: 31

The FB66a cDNA, set out in SEQ ID NO: 3, is 4389 nucleotides in length and, from nucleotide 3 to nucleotide 2411, encodes a protein of 803 amino acids with a predicted molecular weight of approximately 90,775 Da. The deduced amino acid sequence for FB66a is set out in SEQ ID NO: 4. The first methionine is encoded at nucleotide 45; the absence of an upstream in frame stop codon makes it unclear whether this residue is an internal methionine or the beginning of the open reading frame.

The DNA sequence of FB85c-2 (SEQ ID NO: 5) was similarly determined using primers M13Rev.1, W48A2, W48A9, W48A4, W48S1, W48A1, W48S6, W48A5, W48A6, W48S2, W48S3, W48S4, W48S5, W48S7, W48A8, and M13. FB85c-2 appeared to include two distinct DNA inserts, only one of which was homologous to WO4835. The region homologous to WO4835 was approximately 2.8 kb in length. The precise sequence at the 5′ end of the insert could not be determined and thus a few hundred bases of sequence in what may be a 5′-untranslated region are not included in the 2573 nucleotide sequence set out in SEQ ID NO: 5. Nucleotide 67 to nucleotide 2406 encodes a protein having 779 amino acid protein (SEQ ID NO: 6) having a predicted molecular weight of 88,353 Da. An in frame upstream stop codon makes it likely that the methionine encoded at nucleotide position 67 is the initiation methionine.

The proteins encoded by FB66a and FB85c-2 have different amino terminal sequences which may be due to alternative splicing. The DNA sequences diverge from each other 5′ of nucleotide 112 in FB66a and nucleotide 104 in FB85c-2. Thus, FB85c-2 has 13 amino acids at the amino terminus that are not found in the FB66a protein. The FB66a protein includes 23 unique amino terminal residues if the initiating methionine at presumed to be encoded at nucleotide 35; the protein includes more than 37 unique amino terminal residues if the open reading frame in the FB66a clone is incomplete.

BLASTN analysis, wherein a query nucleotide sequence is compared against a nucleotide sequence database, of the FB66a sequence revealed no identity with sequences in Genbank, NCBI STS, NCBI HTGS, or NCBI GSS databases. However, two identical sequences were identified in the NCBI EST database.

One sequence was the WO483 5 EST which was used to identify the cDNA clone. The second, AA307865 (SEQ ID NO: 32), derived from a colon cancer cell line KM12C (HCC) showed sequence identity with the 3′ untranslated region of the FB66a and FB85c-2 clones. During the search in which AA307865 was identified, additional EST DNAs were identified presumably encoding putative mouse (EST AA386789, SEQ ID NO: 38) and rat (EST H32734, SEQ ID NO: 33) homologs to the human proteins encoded by FB66a and FB8Sc-2. The mouse sequence was 86% identical to the human sequences and the rat sequence was 81%.

EXAMPLE 4 Analysis FB85c-2 and FB66a Protein

The PDEs encoded by clones FB85c-2 and FB66a were designated PDE8A1 and PDE8A2, respectively. Both PDE8A proteins, having complete amino acid sequence identity beyond the point of divergence discussed above, are most similar to human PDE2A, PDE5A, PDE6A, PDE6B, and PDE6C. Tables 1 and 2 show percent amino acid identity between PDE8A and PDE2A, PDE5A and PDE6A.

PDE8A1 and PDE8A2 share homology with other PDEs over the catalytic region (amino acids 492 through 748 in PDE8A1) and with the putative cGMP binding domain conserved in the amino terminal region of the PDE2A, PDE5A, PDE6A, PDE6B, AND PDE6C. The potential cGMP binding domain of PDE8A extends from amino acids 75 to amino acid 445 in the PDE8A1 polypeptide. Within the cGMP binding domains of PDE2A, PDE5A, PDE6A, PDE6B, and PDE6C, there are two internal repeats designated “a” and “b,” and each repeat contains a series of conserved amino acids [McAllister-Lucas, et al., J. Biol. Chem. 268:22863-22873 (1993)]. In the corresponding “b” repeat region of PDE8A, all of the conserved amino acids are found; in the corresponding “a” repeat region, only some of the conserved residues were detected. An aspartate residue, shown to be essential for the cGMP binding by bovine PDE5A [McAllister-Lucas, et al., J. Biol. Chem. 270: 1-9 (1995)] is not present in the “a” repeat region of PDE8A. It is therefore uncertain whether this region in PDE8A functions to bind cGMP.

TABLE 1 PDE8A Identity in the Entire Protein PDE 2A 5A 6A 8A 2A 100 19 16 28 5A 100  23 28 6A 100  21 8A 100 

TABLE 2 PDE8A Identity in the Catalytic Domain PDE 2A 5A 6A 8A 2A 100 38 33 41 5A 100  42 46 6A 100  37 8A 100 

EXAMPLE 5 Expression of Recombinant PDE8A

An expression construct for PDE8A was generated that included DNA sequences 3′ from the point of divergence of PDE8A1 and PDE8A2 through the stop codon. The expression construction included DNA encoding an eight amino acid epitope tag. The so-called “FLAG tag,” comprising the peptide sequence set out in SEQ ID NO: 34, was added to the amino terminus in order that the protein could be identified by Western blotting techniques using an anti-FLAG M2 antibody (Eastman Kodak, Rochester, N.Y.) which specifically recognized the peptide of SEQ ID NO: 34.

Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys SEQ ID NO: 34

Sequences encoding an initiating methionine at the proteins amino terminus was also added.

As a first step in constructing the expression plasmid, PCR was performed using FB66a DNA as a template using primers set out in SEQ ID NOs: 35 (below) and W48A2 (SEQ ID NO: 10, p. 14) in a reaction mixture containing 2 μl each primer (stock 100 μg/ml), 2 μl 10×PCR buffer II (Perkin Elmer), 2 μl 10× stock of each nucleotide (stock 2 mM), 1.2 μl MgCl₂ (stock 25 mM), 0.09 μl 5 Units/μl taq polymerase (Perkin Elmer), FB66a DNA and water to bring the reaction mixture to 20 μl. In the 5′ primer (SEQ ID NO: 35), an NcoI site is in bold and the FLAG tag encoding region is underlined.

CAGTCAGCTAGCCGCCATGGACTACAAGGAC-GACGATGACCAAGTTGACTGATGAAAAGGTG SEQ ID NO: 35

PCR was carried out in a Perkin Elmer DNA Thermal Cycler under the following conditions: 94° C. for 4 minutes followed by 30 cycles of 94° C. for one minute, 50° C. for one minute, and 72° C. for two minutes.

The resulting PCR product was digested with NcoI and KpnI, gel purified, and subdloned into Bluescript SKII⁺ vector previously digested with the same enzymes. The Bluescript vector had previously been modified to include a SacI/NcoI alcohol dehydrogenase 2 (ADH2) promoter fragment removed from a YEpC-PADH2d vector [Price, et al., Meth. Enzymol. 185:308-315 (1990)]. The resulting plasmid was designated W48pcr1.

A KpnI/SstI fragment containing the 3′ portion of the open reading frame was isolated from a FB66a cDNA and inserted into W48pcr1 previously digested with KpnI and EcoRV. The resulting plasmid was designated W485.1.

A SacI/KpnI fragment containing the ADH2 promoter and the 5′ portion of the PDE8A gene was isolated from W49pcr1. A KpnI/SalI fragment containing the 3′ region of PDE8A was isolated from W485.1. The two fragments were ligated into the yeast expression vector YEpC-PADH2d that had been previously digested with SacI and SalI. The resulting plasmid was designated W48-2ADH2 and was deposited on Oct. 2, 1997 under the terms of the Budapest Treaty with the American Type Culture Collection (A.T.C.C.), 12301 Parklawn Drive, Rockville, Md. 20852. The bacterial strain bearing plasmid W48-2ADH2 was assigned accession number ATCC 98552. The DNA sequences generated by PCR and the DNA sequences at the PDE8/vector junctions were determined to insure proper plasmid construction. Upon confirmation of the sequence, the plasmid was transformed into a yeast strain BJ2-54 lacking endogenous PDE activity (ura3-52; trp1; leu2; cir°; gal2; pep4-3; prb1-1122; prc1-402; ΔPDE1:: URA3; HIS3; ΔPDE2:: TRP1).

The host cells were grown overnight in SC-leu selective media including 2% glucose, diluted to 1-2×10⁵ cells/ml and subsequently grown to a density of 10⁷ cells/ml in the same media. The presence of the expression plasmid appeared to increase the doubling time for cell growth two- to three-fold even under non-inducing conditions. The cells were collected by centrifugation, washed with YEP media including 3% glycerol, resuspended in YEP/3% glycerol at a density of 10⁷ cells/ml, and grown for 24 hours prior to harvest. Cells were frozen until use.

Frozen cell pellets (0.06 ml) were thawed and suspended in 0.2 ml lysis buffer containing 100 mM MOPS, pH 8.0, 200 mM NaCl, 2 μM ZnSO₂, 2 mM dithiothreitol, and 10 μg/ml each protease inhibitors pepstatin, leupeptin, and aprotinin. Approximately 0.2 ml of 0.5 mm glass beads were added to the cells which were then lysed with four 30-second cycles of vortexing. The lysate was aspirated and the beads were washed twice with 0.3 ml lysis buffer. The lysate was combined with the washes to generate the yeast extract. In some experiments the lysate was fractionated by centrifugation at 105,000×g for thirty minutes.

Western analysis was carried out on yeast extract containing the recombinant protein as follows. Proteins were first separated on SDS-PAGE and transferred to Immobilon-P (Millipore) using standard methods. The protein blots were blocked using 5% non-fat dry milk in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20 (TBST buffer plus milk) for one hour at room temperature. The blots were incubated with anti-FLAG M2 antibody (discussed above) at a concentration of 1 μg/ml in TBST buffer plus milk for one hour, after which the blots were washed four times with TBST buffer. The blots were then incubated for one hour with blotting grade affinity purified goat anti-mouse IgG antibody conjugated to horse radish peroxidase (HRP.) (BioRad). The goat IgG was previously diluted 1:10,000 in TBST buffer plus milk. The blots were washed four times with TBST and treated, according to the manufacturer's suggested protocol, with the Renaissance® system (New England Nuclear Life Sciences Products) for enhanced chemiluminescence prior to autoradiography. The majority of the protein detected by the antibody was the size expected for the recombinant protein.

PDE activity was assayed by detection of ³²P-phosphate released from ³²P-cAMP or ³²P-cGMP as described previously [Loughney et al., J. Biol. Chem. 271:796-806 (1996)]. The yeast extract was diluted in 0.5×lysis buffer also containing 0.5 mg/ml bovine serum albumin. Twenty μl of the yeast extract, or diluted yeast extract, was assayed in a 100 μl reaction volume which included an additional 50 mM Tris-HCl (pH 8.0), 5 mM MgCl₂ 1 μM Zn SO₂, and 0.1 mg/ml bovine serum albumin. Protein concentration was assayed by the method of Bradford.

PDE8A was observed to hydrolyze both cAMP and cGMP. In unfractionated lysates, the specific activity for cAMP was 3.9 nmol/min/mg and for cGMP was 7.6 nmol/min/mg. Fractionation revealed that 20-40% of the total activity was associated with the high speed supernatant fraction. Kinetic analysis of the activity with cAMP as substrate suggested the presence of both low and high K_(m) forms of the enzyme in a 1:1 activity ratio. The estimated K_(m) values were 0.2 μM and 350 μM. Analysis of the high speed pellet suggested that the same species were present but in a high K_(m) low K_(m) activity ratio of 1:4. Kinetic analysis with cGMP as substrate also suggested the presence of low and high forms of the enzyme. In these analyses, K_(m) values were estimated to be 3 μM and 300 μM.

The IC₅₀ values for inhibition of PDE8A activity were determined using a set of isozyme-selective PDE inhibitors and the non-selective inhibitor isomethyl butyl xanthine (IBMX. Since these assays were performed at a cAMP concentration of 60 nM, the IC₅₀ values reflect inhibition of the low K_(m) form only. The results are set out in Table 3 with values shown in micromolar units.

TABLE 3 PDE8 Inhibition with Isozyme-specific PDE Inhibitors Target PDE IC₅₀ for IC₅₀ for Fold Compound Family Target Family PDE8 Difference IC224 PDE1 0.08-0.008 2.7 38-338 EHNA PDE2 2   65    31 Cilostamide PDE3 0.02 12   750 IC197 PDE4 0.02 14   714 DMPPO PDE5  0.016 1.1  66 IBMX Non-selective 1-40 4.6 0.12-4.6 

The IC₅₀ values for each of the selective inhibitors were at least 30 times higher against PDE8 than against their target isozymes which suggests that the inhibitory profile of PDE8 is distinct from that of PDEs 1-5. The hydrolysis of cAMP and cGMP clearly distinguishes the enzymatic activity of PDE8A from that of PDE6 and PDE7A. The IC₅₀ of the non-selective inhibitor IBMX for PDE8 was in the range observed for known human PDEs suggesting that the catalytic site of PDE8 resembles those of other human and mammalian PDEs and is distinct from lower eukaryotic forms that are insensitive to IBMX.

EXAMPLE 6 Northern Analysis of PDE8A Expression

Northern analysis of PDE8A expression was carried out using a human multiple tissue blot (Clontech, Palo Alto, Calif.). The 327 base probe was extended from nucleotide 1767 to nucleotide 2293 in SEQ ID NO: 3. Riboprobe preparation and hybridization conditions were as previously described [Loughney, et al. supra].

Results showed a 9.5 kb mRNA in all tissues examined but band intensity varied. The signal was strongest in heart, brain, and kidney; the signal was weaker in liver, placenta, pancreas, and skeletal muscle. The signal was weakest in lung.

EXAMPLE 7 Chromosome Mapping of Human PDE8A

Yeast artificial chromosomes (YACs) containing the human PDE8A gene were isolated from a panel of human YACs purchased from Research Genetics and screened by PCR as follows.

The YAC super-pools were screened with two nested pairs of primers. In the first screening reaction, sense primer W48S8 (SEQ ID NO: 36) was paired with the anti-sense primer W48A10 (SEQ ID NO: 37). PCR was carried out with 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 2 mM MgSO₄, 0.2 mM of each dNTP, 10 μg/ml of each primer, 0.5 units of Taq polymerase (Perkin-Elmer) and 1.5 μl of YAC pool DNA as template. Reactions were carried out for 30 cycles, each cycle consisting of one minute at 94° C., two minutes at 60° C., and four minutes at 72° C. After the first round of amplification, the reaction products were reamplified with the internal pair of primers W48S12 (SEQ ID NO: 36) and W48A12 (SEQ ID NO: 37).

W48S12 CCAGAAGGGGTACTTTTCC SEQ ID NO: 36 W48A12 CATTGTCCTGAGGCTGTGG SEQ ID NO: 37

The reactions were carried out as described above except that the template was 1 μl of a 1:10 dilution (in water) of the first round reaction. Super-pools yielding the correct size PCR product were identified and the corresponding sub-pools were screened with the same nested pairs of primers under the same conditions to identify unique addresses for YACs containing PDE8A.

Yeast strains harboring the relevant YACs were purchased from Research Genetics. In order to verify the presence of the PDE8A gene in the various YACs, DNA was prepared from each strain and analyzed by PCR with primers W48S8 and W48A10. DNA was prepared from each strain according to a method previously described [Hoffman and Winston, Gene 57:267-272 (1987)] but modified as follows. Strains were grown overnight at 30° C. in YEP media containing glucose. Ten ml of culture was peueted by centrifugation and resuspended in 200 μl of aqueous buffer containing 10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM Na₂EDTA, 1% SDS, and 2% Triton-X100. The cells were lysed by vortexing in the presence of 200 μl of phenol/chloroform (1:1 mixture) and 100 μl of glass beads (425-600 μm). Following lysis, 200 μl of TE Buffer (10 mM Tris, pH 8.0, 1 mM Na₂EDTA) was added and the sample was centrifuged to separate the phases. The organic phase was extracted again with 200 μl of aqueous buffer. The pooled aqueous phase was treated with 100 units of bovine pancreatic RNase (Boehringer Mannheim) for 1 hour at 37° C. and the sample was extracted with phenol/chloroform, re-extracted with chloroform, and ethanol precipitated according to established methods. The resultant pellet was resuspended in 50 μl TE Buffer. PCR was carried out as described above except that the reaction volume was 25 μl and the template consisted of 1 μl of the relevant yeast DNA preparation.

Three human YACs containing the PDE8 gene were identified with addresses 805B6, 919H10 and 920A3 (as per the CEPH designation). According to information in the Center for Genome Research database (Whitehead), the three YACs overlap one another and are part of a singly-linked contig (WC6.16) on human chromosome 6. Two sequence tagged sites within this contig (D6S305 and D6S411) have been placed on the chromosomes 6 genetic map at a position 167 cM from the end of 6p in work at the Center for Genome Research; D6S305 has been mapped to a position 173 cM from the end of 6p in work at CEPH-Genethon. Three other YACs within the WC6.16 contig (932F1, 956B1 and 947D5) have been mapped by florescence in situ hybridization at CEPH-Genethon. The hybridization signals fall between 0.94—and 0.99 fractional length units from the end of 6p. According to the CEPH integrated summary map [Chumakov et al., Nature 377 (Supp):175-297 (1995)], this region corresponds to the cytogenetic region 6q26-27.

Heritable defects that have been associated with this region of the human genome include retina cone degeneration (OMIM database), Insulin-dependent diabetes mellitus [Davies et al. Nature 371:130-136 (1994); Luo et al. Am. J. Hum. Genet. 57:911-919 (1995)] and juvenile onset parkinsonism [Matsumine et al. Am. J. Hum. Genet. 60:588-596 (1997)]. In addition, loss of heterozygosity (LOH) is frequently observed in this region in a variety of different cancer cells, including Burkitt's lymphoma [Parsa et al. Genes, Chromosomes & Cancer 9:13-18 (1994)], astrocytoma [Liang et al. Neurology 44:533-536 (1994)], gastric carcinoma [Queimado et al. Genes, Chromosomes & Cancer 14:28-34 (1995)], parathyroid adenoma [Tahara et al. Cancer Res. 56:599-605 (1996)] and ovarian carcinoma [Cooke et al. Genes, Chromosomes & Cancer 15:223-233 (1996); Saito et al. Cancer Res. 56:5586-5589 (1996)]. LOH has been suggested to indicate the presence of a tumor suppressor gene in the affected region [Weinberg, Science 254:1138-1146 (1991)]. Due to its widespread expression, it is possible that mutation of the PDE8 gene may be involved in all or some of these genetic abnormalities.

EXAMPLE 8 Verification that PDE8A1 and PDE8A2 Represent Splice Variants and Efforts to Extend the 5′ Sequence of PDE8A2

To verify that PDE8A1 and PDE8A2 represent 5′ splice variants, two approaches were taken. First, PCR analysis revealed that, in genomic DNA, neither PDE8A1 nor PDE8A2 sequences were adjacent the DNA sequence of the common region. The genomic sequences upstream of the common region were present in a third PDE8A cDNA, FB74b, which was identified in the group of six original clones that hybridized to the 5′ end of probe WO4835 described in Example 2. The partial sequence (755 nucleotides at the 3′ end) of clone FB74b is set out in SEQ ID NO: 39. The FB74b cDNA diverged from FB85c-2 and FB66a at the same position as FB85c-2 and FB66a diverged from each other, but the FB74b clone did not maintain the open reading frame. In the FB74b sequence 5′ to the point of sequence divergence from the FB66a and FB85c-2 clones, an in-frame stop codon was closer to the point of divergence than an initiating methionine codon indicating that, if FB74b represented a cDNA rather than an unspliced precursor, the initiating methionine would necessarily be located in the sequence common to both FB66a and FB85c-2.

PCR analysis was performed using one primer designated FB74bS1 (SEQ ID NO: 40) within the FB74b upstream sequences and a second primer designated W48A9 (SEQ ID NO: 11) within the sequences common to FB74b, FB66a, and FB85c-2.

FB74bS1 GTTAGATGAGAGGTTGCTGG SEQ ID NO: 40

Using 1 μg of human genomic DNA as template, a band was amplified having the same size as the one amplified using FB74b as template, indicating that the sequences unique to FB74b and the common region were adjacent in genomic DNA. Thus, the FB74b sequence may represent an unspliced intron or may represent a third splice variant that would encode a protein with an initiating methionine within the common region. In either case, the FB85c-2 and FB66a sequences are presumably generated by splicing.

Secondly, 5′ RACE analysis was performed using RNA isolated from human cortex, cerebellum, heart, liver and lung tissues. RNA was isolated from frozen tissue fragments as described [Loughney et al, J. Biol. Chem. 271: 796-806 (1996)] and poly A⁺ mRNA was selected using the Fast Track™ mRNA isolation system (Invitrogen). Double stranded cDNA was prepared using 5 μg poly A⁺ mRNA and a cDNA synthesis kit (Boehringer Mannheim). The cDNA was ligated to a linker formed by annealing oligonucleotides L15 (SEQ ID NO: 41) and L30 (SEQ ID NO: 42).

L15 GTATGCTAATCTCAG SEQ ID NO: 41 L30 CAACTCGAATTCCTTGACAGATTAGCATAC SEQ ID NO: 42

For the 5′ RACE, the linker-ligated cDNA was amplified by PCR using oligonucleotides L18 (SEQ ID NO: 43) and W48A13 (SEQ ID NO: 44).

L18 CAACTCGAATTCCTTGAC SEQ ID NO: 43 W48A13 GTTGTTCTTCCTCTTCAGCC SEQ ID NO: 44

The reaction contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.2 mM of each dNTP, 10 μg/ml of each primer and 1 μl of linker-ligated cDNA in a reaction volume of 25 μl. Following heating step at 94° C., PCR was initiated by the addition of 0.1 unit of Taq polymerase (Boehringer Mannheim) and continued with 30 cycles of one aminute at 94° C., two minutes at 60° C., and four minutes at 72° C.

The products of the PCR reaction were diluted ten-fold with water and used as template in a second PCR reaction with oligonucleotides L21 (SEQ ID NO: 45) and W48A9S (SEQ ID NO: 46) under the same conditions described above.

L21 CAACTCGAATTCCTTGACAGA SEQ ID NO: 45 W48A9S GATCGTCGACCTGTCTCTGCACTAACAC SEQ ID NO: 46

DNA amplified in the second PCR reaction was cleaved with EcoRI and SalI and ligated into the vector Bluescript (Stratagene) previously digested with the same enzymes.

Initially, DNA sequences in five plasmids from each tissue source were examined and both PDE8A1 and PDE8A2 5′ sequences were found among the cDNAs isolated. FB74b 5′ sequences were also obtained, as were several sequences, each isolated only once, that could represent yet additional splice variants or unrelated DNA sequences.

Because none of the PDE8A2-like cDNAs extended further 5′ than did the original FB66a cDNA, additional PDE8A2 RACE clones were analyzed in an attempt to extend the 5′ end sequence. An additional five lung PDE8A2 cDNAs were identified and sequenced, but none extended the PDE8A2 sequence.

A second round of RACE PCR was repeated using the L21 primer (SEQ ID NO: 45) with primer W48A14S (SEQ ID NO: 47).

W48A14S GATCGTCGACAAGCACTCGGTCAGCCTTCG SEQ ID NO: 47

The resultant clones were screened by PCR and the longest ones were chosen for sequencing. Only two clones were longer than the original FB66a cDNA and they extended the 5′ sequence 8 and 12 bp, respectively, in the untranslated region. The FB66a sequences were extended with 5′-CCCAGGGCGCCA. The extreme 5′ end of FB66a is very GC rich which may contribute to the difficulty in isolating full length cDNAs.

EXAMPLE 9 Expression and Characterization of PDE8A

The recombinant PDE8A described in Example 5 existed in both low affinity and high affinity forms in yeast extract. Because of the possibility that the low affinity form represented partially inactive enzyme, PDE8A expression was carried out in sf9 and COS cells in an attempt to either obtain a homogeneous enzyme or determine if the two kinetic forms are always expressed from the cDNA.

The PDE8 sf9 expression construct was generated with a 3′ KpnI-SalI fragment from plasmid W485.1 (described in Example 5) and a 5′ fragment generated by PCR as follows. The primers FLAG-1 (SEQ ID NO: 48) and W48A4 (SEQ ID NO: 12) were used in PCR with PDE8 COS-1 DNA (described below) as template.

FLAG-1 GATCGGATCCACCATGGACTACAAGG SEQ ID NO: 48

PCR was performed as described in Example 8 except that 2 mM MgSO₄ was used in place of MgCl₂ and 0.02 U Taq polymerase was used. Following a four minute initial incubation at 94° C., 30 cycles were performed with one minute at 94° C., one minute at 50° C., and two minutes at 72° C. The 5′ amplification product was cleaved with BamHI and KpnI, gel purified, and ligated with the 3′ fragment into vector pFASTBAC (Gibco BRL, Gaithersburg, Md.) previously digested with BamHI and SalI. The resulting plasmid was designated pFBRPDE8. All PCR amplification products and all new junctions were verified by sequencing.

Recombinant viral stocks were produced using the FastBac system (Gibco BRL) according to the manufacturer's suggested protocol and protein expression was carried out as follows. Sf9 cells were grown at 27° C. in CCM3 media (Hyclone, Logan, Utah) containing 50 U/ml penicillin and 50 μg/ml streptomycin sulfate (Gibco). Exponentially growing cells were infected at a multiplicity of approximately two virus per cell and incubated for 48 hours. Cells were collected by centrifugation, washed with CMF-PBS (2.7 mM KCl, 1.5 mM KH₂PO₄, 137 mM NaCl, 8.1 mM Na₂PO₄), and the pellets were frozen and stored at −80° C. until use. Cells were lysed in buffer (50 mM MOPS pH 7.2, 10 μl M zinc sulfate, 1 mM DTT, 2 mM benzamidine, 10 μg/ml each pepstatin, leupeptin, and aprotinin, and 20 μg/ml each calpain I and calpain II inhibitors) by vortexing in the presence of an equal volume of glass beads (acid washed, 0.5 mm, Sigma) and PDE activity was determined as described in Example 5.

In the sf9 extract, 45.4 nmol/min/mg PDE activity was detected for cAMP hydrolysis (100 μM substrate) and 69.4 nmol/min/mg for cGMP hydrolysis (100 μM substrate). The background PDE activity was negligible. The PDE8A activity appeared to be a mixture of high and low affinity forms as detected in yeast extracts as described in Example 5.

For expression in COS cells, PDE8 COS-1 was generated by combining 3′ KpnI/SalI fragment from plasmid W485.1 (Example 5) and a NheI/KpnI fragment obtained by cleavage of a PCR amplification product from a reaction including FB66a cDNA as a template with primers W48A2 (SEQ ID NO: 10) and ATG (SEQ ID NO: 35). Conditions for the PCR included an initial incubation for four minutes at 94° C. followed by 30 cycles of one minute at 94° C., one minute at 50° C. and two minutes at 72° C. in a Peridn Elmer Cetus DNA thermal cycler. The resulting 5′ fragment and the 3′ fragment described above were ligated into vector pC1neo (Promega, Madison, Wis.) which had been previously digested with NheI and SalI.

Semi-confluent COS cells growing in 15 cm dishes were washed once with 25 ml DMEM (Dulbecco's Modified Eagle Media, 100 U/ml penicillin and 100 μg/ml streptomycin sulfate, GIBCO), after which 14 ml of DMEM/DEAE-dextran/chloroquine was added per plate. DMEM/DEAE dextran/chloroquine is compressed of 75 ml DMEM and 30 μl 0.25 M chloroquine in PBS (2.7 mM KCl, 1.5 mM KH₂PO₄, 137 mM NaCl, 8.1 mM Na₂PO₄, 0.9 mM CaCl₂ 0.5 mM MgCl₂), together with 0.75 ml 50 μg/ml DEAE-dextran (Pharmacia, Uppsala, Sweden). Twenty μg of plasmid DNA in 135 μl Tris/EDTA buffer (TE) was added per plate and the plates were incubated for two hours at 37° C. in 5% CO₂. The media was removed and 12 ml of 10% DMSO/PBS was added for one minute and removed. The cells were washed once with 25 ml DMEM, after which another 25 ml of DMEM containing 10% fetal calf serum (Hyclone, Logan, Utah) was added and the cells were incubated overnight at 37° C. in 5% CO₂. The media was removed and the monolayer was washed with 25 ml of CMF-PBS. Six ml of a solution containing 0.05% trypsin/0.5 mM EDTA (Gibco) was added and the cells were incubated five minutes at 37° C. Cells were removed from the plates by trituration and transferred to conical centrifuge tubes. The plates were washed with six ml of complete DMEM to harvest any remaining cells and the wash solution was added to the centrifuge tubes. Cells were pelleted by centrifugation for five minutes at approximately 340×g, resuspended in five ml complete DMEM, removed to a 15 cm tissue culture dish containing 20 ml complete DMEM, and incubated overnight in 5% CO₂.

The monolayer was washed two times with CMF-PBS, incubated five minutes at 37° C. in vemne (0.5 mM Na₂EDTA.2H₂O, 137 mM NaCl, 2.68 mM KCl, 8.1 mM Na₂HPO₄, 1.1 mM glucose, pH 7.4), and harvested as described above. Pelleted cells were washed with CMF-PBS, frozen in dry ice, and stored at −80° C. until use. Cells were lysed in buffer (50 mM MOPS, pH 7.2, 10 μM zinc sulfate, 1 mM DTT, 2 mM benzamidine, 10 μg/ml each pepstatin, leupeptin, and aprotinin, and 20 μg/ml each calpain I and calpain II inhibitors) by passage through a French pressure cell (SLM Instruments) at 20,000 psi and PDE activity was determined as described in Example 5.

PDE8A expression was low in the COS cell extract and could not be accurately characterized due to the high level of background activity from endogenous PDEs. In order to more fully characterize the COS cell expression product, the enzyme including a FLAG tag at the amino terminus (Example 5) is purified from a 100,000×g supernatant of cell extract using an anti-FLAG M2 affinity column (Sigma) according to the manufacturer's suggested protocol. In order to more accurately characterize yeast PDE8A activity, expression of a recombinant protein that is truncated at the amino terminus but retains the catalytic region is carried out as described in Example S in an attempt to obtain a homogenous protein.

EXAMPLE 10 Production of Anti-PDE8A Antibodies

A GST fusion protein was produced in E. coli to provide an antigen for generation of monoclonal antibodies to PDE8A. An EcoRI fragment from FB70a (a PDE8A cDNA that includes nucleotides 182-1330 of FB85c-2 and which was one of the nine clones originally identified which hybridized to the full length WO4835 probe described in Example 2) was inserted into the ECoRI site of pGEX5X1 (Phannacia) and the resultant construct was transformed in the E. coli strain XL1 Blue. A GST-PDE8A fusion protein including 382 amino acids from PDE8A was produced from this construct following induction with IPTG. The fusion protein was isolated using SDS-PAGE, the band of appropriate size excised from the gel following staining with cold 0.4 M KCl, and the protein obtained from the acrylamide by electroelution. The elution product was dialyzed against PBS and concentrated using Centriprep 10 and Centricon columns (Amicon, Beverly Mass.) prior to being injected into mice.

On day 0, four Balb/c mice were pre-bled and injected subcutaneously with a panel of antigens including 30 μg/mouse GST-PDE8 fusion protein in complete Freund's adjuvant in 200 μl total volume. The same injections were repeated at weeks three and nine in incomplete Freund's adjuvant. Ten days after the last immunization, test bleeds were obtained and screened by antigen capture ELISA and Western analysis.

In the ELISA, Immulon 4 plates (Dynex, Cambridge, Mass.) were coated at 4° C. with 50 μl/well of a solution containing 2 μg/ml GST-PDE8 in 50 mM carbonate buffer, pH 9.6. Plates were blocked with 0.5% fish skin gelatin (Sigma) for 30 minutes and 50 μl serum diluted in PBS with 0.5% Tween 20 (PBST) was added. Serum dilutions ranged from 1:100 to 1:102,400 and were obtained by a series of doubling dilutions. After incubation at 37° C. for 30 minutes and washing three times with PBST, 50 μl of horseradish peroxidase-conjugated goat anti-mouse IgG(fc) antibody (Jackson) (diluted 1:10000 in PBST) was added. Plates were incubated as above and washed four times with PBST. Antibody was detected with addition of tetramethyl benzidine (Sigma Chemical, St. Louis, Mo.) and the color reaction was stopped after five minutes with the addition of 50 μl of 15% H₂SO₄. Absorbance at 450 nM was measured on a plate reader.

For Western analysis, SDS-PAGE gels were run with approximately 10 μg yeast PDE8 extract and approximately 200 ng of gel-purified GST-PDE8 and the proteins were transferred to Immobilon-PVDF. A standard enhanced chemiluminescence (ECL) Western blot protocol was performed using BioRad goat anti-mouse IgG horseradish peroxidase as the secondary antibody.

In preparation of hybridomas, splenocytes from mice giving a positive result from the ELISA and/or Western blotting protocols above, were fused to NS-1 cells in a ratio of 5:1 by standard methods using polyethylene glycol 1500 (Boehringer Mannheim) (Harlow and Lane, Antibodies, a laboratory Manual, Cold Spring Harbor laboratory, 1988). The fused cells were resuspended in 200 ml RPMI containing 15% FBS, 100 mM sodium hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer Mannheim) and 1.5×10⁶ murine thymocytes/ml and dispensed into ten 96-well flat bottom tissue culture plates (Corning, United Kingdom) at 200 μl/well. Cells were fed on days 2, 4, and 6 days post fusion by aspirating approximately 100 μl from each well with an 18 G needle (Becton Dickinson) and adding 100 μl/well plating medium described above except containing 10 units/ml IL-6 and lacking thymocytes. On days 9 to 12, supernatants from the fusion wells were screened by antigen capture ELISA using GST and GST-PDE8 and by ECL Western analysis as described above.

A positive signal of the expected size was obtained on both lanes of the Western blot using mouse blood and a monoclonal antibody with very weak reactivity to the yeast recombinant protein was obtained in the subsequent fusion. The entire procedure is repeated using 50 μg antigen/mouse to obtain more strongly immunoreactive monoclonal antibodies.

EXAMPLE 11 Analysis of PDE8A Expression by in situ Hybridization

Expression of PDE8A was examined in tissue sections by in situ hybridization as described below.

Preparation of Probe

An Xhol/EcoRI restriction enzyme fragment from the cDNA FB70a (corresponding to nucleotides 571 to 1226 of SEQ ID NO: 1) was subdloned into a Bluescript vector (Stratagene, La Jolla, Calif.) to generate an expression plasmid designated PDE8XR2A. The plasmid was cleaved with Xhol and transcribed (see below) with T3 polymerase to generate an antisense probe. A sense probe was generated by cleaving PDE8XR2A with EcoRI and transcribing with T7 polymerase. The PDE8A templates were transcribed using a RNA Transcription kit (Stratagene, La Jolla, Calif.) in a reaction containing 5 μl of 5×transcription buffer (Stratagene), 30 mM DIT (Stratagene), 0.8 mM each ATP, CTP, GTP (10 mM (Stratagene), 40 U RNase Block II (Stratagene), 12.5 U T3 or T7 polymerase (Stratagene), and 300 ng linearzed plasmid template, 50 μCi ³⁵S-UTP (greater than 1000 Ci/mmol, Amersham, Arlington Heights, Ill.). The mixture was incubated at 37° C. for one hour after which the template DNA was removed by addition of 1 μl of RNase-free DNase I (Stratagene) and incubation for 15 minutes at 37° C. The probe was hydrolyzed by adding 4 μl 1 M NaHCO₃ and 6 μl 1 M Na₂CO₃ for 22 minutes at 60° C. and the reaction mixture was neutralized by addition of 25 μl of a solution containing 100 μl 3 M sodium acetate, 5 μl acetic acid (VWR, So. Plainfield, N.J.), and 395 μl dH₂O. A Quick Spin G50 RNA column (5′-3′ Inc., Boulder, Colo.) was prepared according to the manufacturer's suggested protocol. The probe was placed in the center of the column and the column centrifuged for four minutes at 1,000 rpm in a desk top centrifuge. The column flow through was mixed with 50 μl dH₂O, 2 μl of a 10 mg/ml tRNA solution, 10 μl 3 M sodium acetate, and 200 μl 100% ethanol (VWR) and the resulting mixture was incubated at −20° C. overnight. The probe solution was microfuged for 15 minutes at 4° C., the supernatant was removed, and the pellet was resuspended in 40 μl 1×TBE containing 1 μl of 0.1 M DTT. The probe was stored at −70° C. until the in situ hybridization assay was performed.

Preparation of Tissue Samples and in situ Hybridization

Tissues (National Disease Research Interchange, Philadelphia, Pa. and Cooperative Human Tissue Network, Philadelphia, Pa.) were sectioned at 6 μm and placed on Superfrost Plus slides (VWR). Sections were fixed for 20 minutes at 4° C. in 4% parafornaldehyde (Sigma, St. Louis, Mo.). The slides were rinsed in three changes of 1×CMF-PBS, dehydrated with three successive washes with 70% ethanol, 95% ethanol and 100% ethanol , and dried for 30 minutes at room temperature. The slides were placed in 70% formamide (J. T. Baker) in 2×SSC for two minutes at 70° C., rinsed in 2×SSC at 4° C., dehydrated through 70%, 95% and 100% ethanol washes, and dried for 30 minutes at room temperature.

A prehybridization step was performed by placing the slides in an airtight box containing a piece of filter paper saturated with box buffer containing 50% formamide (J. T. Baker) in 4×SSC. Each section was covered with 100 μl of rHB2 buffer consisting of 10% dextran sulfate (Sigma), 50% formamide (J. T. Baker, Phillpsburg, N.J.), 100 mM DTT (Boehringer Mannheim, Indianapolis, Ind.), 0.3 M NaCl (Sigma), 20 mM Tris, pH 7.5, 5 mM EDTA (Sigma), and 1×Denhardt's solution (Sigma) and the slides were incubated at 42° C. for 1 hour. The probe, as described above, was prepared by mixing 4×10⁵ cpm/tissue section with 5 μl of a 10 mg/ml tRNA solution per section and heating the mixture at 95° C. for three minutes. Ice cold rHB2 buffer was added to bring the final volume to 20 μl/section. The probe containing solution (20 μl/section) was added to 100 μl rHB2 buffer previously applied. The slides were incubated at 55° C. for 12 to 16 hours. Following hybridization, the slides were washed once in 4×SSC containing 10 mM DTT for one hour at room temperature, once in 50% deionieed formamide (J. T. Baker), 1×SSC, and 1 mM DTI for 40 minutes at 60° C., once in 2×SSC for 30 minutes at room temperature; and once in 0.1×SSC for 30 minutes at room temperature. The sections were dehydrated through 70%, 95%, and 100% ethanol washes and air dried for 30 minutes. The slides were dipped in Kodak NTB2 nuclear emulsion, dried for one to three hours at room temperature in the dark and stored in the dark at 4° C. with desiccant until time of development. The slides were developed in 4° C. Kodak Dektol developer for four minutes, dipped four times in 4° C. dH₂O, and placed in 4° C. Kodak fixer for four minutes. The slides were rinsed in dH₂O and a standard H&E stain was performed as follows.

The slides were rinsed in dH₂O and stained with hematoxylin and eosin by transfer of the slides through a series of the following step: five minutes in formaldehyde/alcohol (100 ml formaldehyde, 900 ml 80% ethanol); three rinses in water for a total of two minutes; five minutes in 0.75% Harris hematoxylin (Sigma); three rinses in water for a total of two minutes; one dip in 1% HCl/50% ethanol; one rinse in water; four dips in 1% lithium carbonate; ten minutes in tap water; two minutes in 0.5% eosin (Sigma); three rinses in water for a total of two minutes; two minutes in 70% ethanol; three one minute rinses in 95% ethanol; two one minute rinses in 100% ethanol; and two two minutes rinses in xylene. Slides were mounted with cytoseal 60 (Stephens Scientific, Riverdale, N.J.).

The signals obtained with an antisense PDE8A probe were compared to the control signals generated by a sense PDE8A probe and any signal specific to the antisense probe was assumed to represent PDE8A expression. PDE8A signal was detected throughout much of the cerebellum, in a subset of cells in the seminiferous tubules of the testes, on scattered cells of yet undetermined origin in skeletal muscle, in granulosa cells and ovarian stroma in the ovary, in epithelial cells in the loop of Henle in the kidney and on the smooth muscle of some arterioles in the heart.

These results differ from those obtained by Northern blotting and described in Example 6 in that a moderate signal was detected in heart by Northern blot while the in situ data using this heart sample gave a weak signal. The inconsistency could reflect differences in the tissues from different individuals or level of detection differences inherent in the two methods. The signal in the ovary and the signal in the kidney may indicate that PDE8A is involved in ovulation or in salt and/or water homeostasis, respectively.

Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 48 <210> SEQ ID NO 1 <211> LENGTH: 2298 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(2298) <221> NAME/KEY: misc_feature <222> LOCATION: (868)..(870) <223> OTHER INFORMATION: The amino acid encoded by nucleotides 868-870 is either Pro or Leu <400> SEQUENCE: 1 ttg aca gat gaa aaa gtg aag gca tat ctt tct ctt cac ccc cag gta 48 Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val 1 5 10 15 tta gat gaa ttt gta tct gaa agt gtt agt gca gag aca gta gag aaa 96 Leu Asp Glu Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys 20 25 30 tgg ctg aag agg aag aac aac aaa tca gaa gat gaa tcg gct cct aag 144 Trp Leu Lys Arg Lys Asn Asn Lys Ser Glu Asp Glu Ser Ala Pro Lys 35 40 45 gaa gtc agc agg tac caa gat acg aat atg cag gga gtt gta tat gaa 192 Glu Val Ser Arg Tyr Gln Asp Thr Asn Met Gln Gly Val Val Tyr Glu 50 55 60 cta aac agc tat ata gaa caa cgg ttg gac aca gga gga gac aac cag 240 Leu Asn Ser Tyr Ile Glu Gln Arg Leu Asp Thr Gly Gly Asp Asn Gln 65 70 75 80 cta ctc ctc tat gaa ctg agc agc atc att aaa ata gcc aca aaa gcc 288 Leu Leu Leu Tyr Glu Leu Ser Ser Ile Ile Lys Ile Ala Thr Lys Ala 85 90 95 gat gga ttt gca ctg tat ttc ctt gga gag tgc aat aat agc ctg tgt 336 Asp Gly Phe Ala Leu Tyr Phe Leu Gly Glu Cys Asn Asn Ser Leu Cys 100 105 110 ata ttc acg cca cct ggg ata aag gaa gga aaa ccc cgc ctc atc cct 384 Ile Phe Thr Pro Pro Gly Ile Lys Glu Gly Lys Pro Arg Leu Ile Pro 115 120 125 gct ggg ccc atc act cag ggc acc acc gtc tct gct tat gtg gcc aag 432 Ala Gly Pro Ile Thr Gln Gly Thr Thr Val Ser Ala Tyr Val Ala Lys 130 135 140 tcc agg aaa aca ctg cta gta gaa gac atc ctt gga gat gaa cga ttt 480 Ser Arg Lys Thr Leu Leu Val Glu Asp Ile Leu Gly Asp Glu Arg Phe 145 150 155 160 cca aga ggt act gga ctg gaa tca ggg act cgt atc cag tct gtt ctt 528 Pro Arg Gly Thr Gly Leu Glu Ser Gly Thr Arg Ile Gln Ser Val Leu 165 170 175 tgc tta cca att gtc act gca att ggt gac ttg att ggt att ctc gag 576 Cys Leu Pro Ile Val Thr Ala Ile Gly Asp Leu Ile Gly Ile Leu Glu 180 185 190 ctg tat cgg cac tgg ggc aaa gaa gcc ttc tgt ctt agt cac cag gag 624 Leu Tyr Arg His Trp Gly Lys Glu Ala Phe Cys Leu Ser His Gln Glu 195 200 205 gtt gca aca gca aat ctt gcc tgg gct tca gta gca ata cat cag gtg 672 Val Ala Thr Ala Asn Leu Ala Trp Ala Ser Val Ala Ile His Gln Val 210 215 220 cag gta tgc aga ggc ctt gcc aaa cag aca gaa ttg aat gac ttc cta 720 Gln Val Cys Arg Gly Leu Ala Lys Gln Thr Glu Leu Asn Asp Phe Leu 225 230 235 240 ctc gac gta tca aaa aca tat ttt gat aac ata gtt gca ata gat tct 768 Leu Asp Val Ser Lys Thr Tyr Phe Asp Asn Ile Val Ala Ile Asp Ser 245 250 255 cta ctt gaa cac ata atg ata tat gca aaa aac ctg gtg aat gcc gat 816 Leu Leu Glu His Ile Met Ile Tyr Ala Lys Asn Leu Val Asn Ala Asp 260 265 270 cgt tgt gca ctt ttc cag gtg gac cat aag aac aag gag tta tat tca 864 Arg Cys Ala Leu Phe Gln Val Asp His Lys Asn Lys Glu Leu Tyr Ser 275 280 285 gac cyt ttt gat att gga gag gaa aag gaa gga aaa cct gtc ttc aag 912 Asp Xaa Phe Asp Ile Gly Glu Glu Lys Glu Gly Lys Pro Val Phe Lys 290 295 300 aag acc aaa gag ata aga ttt tca att gag aaa gga att gct ggc caa 960 Lys Thr Lys Glu Ile Arg Phe Ser Ile Glu Lys Gly Ile Ala Gly Gln 305 310 315 320 gta gca aga aca ggg gaa gtc ctg aac att cca gat gcc tat gca gac 1008 Val Ala Arg Thr Gly Glu Val Leu Asn Ile Pro Asp Ala Tyr Ala Asp 325 330 335 cca cgc ttt aac aga gaa gta gac ttg tac aca ggc tac acc acg cgg 1056 Pro Arg Phe Asn Arg Glu Val Asp Leu Tyr Thr Gly Tyr Thr Thr Arg 340 345 350 aac atc ctg tgc atg ccc atc gtc agc cga ggc agc gtg ata ggt gtg 1104 Asn Ile Leu Cys Met Pro Ile Val Ser Arg Gly Ser Val Ile Gly Val 355 360 365 gtg cag atg gtc aac aaa atc agt ggc agt gcc ttc tct aaa aca gat 1152 Val Gln Met Val Asn Lys Ile Ser Gly Ser Ala Phe Ser Lys Thr Asp 370 375 380 gaa aac aac ttc aaa atg ttt gcc gtc ttt tgt gct tta gcc tta cac 1200 Glu Asn Asn Phe Lys Met Phe Ala Val Phe Cys Ala Leu Ala Leu His 385 390 395 400 tgt gct aat atg tat cat aga att cgc cac tca gag tgc att tac cgg 1248 Cys Ala Asn Met Tyr His Arg Ile Arg His Ser Glu Cys Ile Tyr Arg 405 410 415 gta acg atg gaa aag ctg tcc tac cat agc att tgt act tca gaa gag 1296 Val Thr Met Glu Lys Leu Ser Tyr His Ser Ile Cys Thr Ser Glu Glu 420 425 430 tgg caa ggt ctc atg caa ttc acc ctt ccc gtg cgt ctc tgc aaa gaa 1344 Trp Gln Gly Leu Met Gln Phe Thr Leu Pro Val Arg Leu Cys Lys Glu 435 440 445 att gaa tta ttc cac ttt gac att ggt cct ttt gaa aac atg tgg cct 1392 Ile Glu Leu Phe His Phe Asp Ile Gly Pro Phe Glu Asn Met Trp Pro 450 455 460 gga att ttt gtc tac atg gtt cat cgg tcc tgt ggg aca tcc tgc ttt 1440 Gly Ile Phe Val Tyr Met Val His Arg Ser Cys Gly Thr Ser Cys Phe 465 470 475 480 gag ctt gaa aag ttg tgt cgt ttt att atg tct gtg aag aag aac tat 1488 Glu Leu Glu Lys Leu Cys Arg Phe Ile Met Ser Val Lys Lys Asn Tyr 485 490 495 cgg cgg gtt cct tat cac aac tgg aag cat gcg gtc act gta gca cac 1536 Arg Arg Val Pro Tyr His Asn Trp Lys His Ala Val Thr Val Ala His 500 505 510 tgc atg tat gcc ata ctt cag aac aat cac acg ctt ttc aca gac ctt 1584 Cys Met Tyr Ala Ile Leu Gln Asn Asn His Thr Leu Phe Thr Asp Leu 515 520 525 gag cgc aaa gga ctg ctg att gcg tgt ctg tgt cat gac ctg gac cac 1632 Glu Arg Lys Gly Leu Leu Ile Ala Cys Leu Cys His Asp Leu Asp His 530 535 540 agg ggc ttc agt aac agc tac ctg cag aag ttc gac cac cct ctg gcc 1680 Arg Gly Phe Ser Asn Ser Tyr Leu Gln Lys Phe Asp His Pro Leu Ala 545 550 555 560 gct ctc tac tcc act tcc acc atg gag cag cac cac ttc tcc cag act 1728 Ala Leu Tyr Ser Thr Ser Thr Met Glu Gln His His Phe Ser Gln Thr 565 570 575 gtg tcc atc ctc cag ttg gaa ggg cac aat atc ttc tcc act ctg agc 1776 Val Ser Ile Leu Gln Leu Glu Gly His Asn Ile Phe Ser Thr Leu Ser 580 585 590 tcc agt gaa tat gag cag gtg ctt gag atc atc cgc aaa gcc atc att 1824 Ser Ser Glu Tyr Glu Gln Val Leu Glu Ile Ile Arg Lys Ala Ile Ile 595 600 605 gcc aca gac ctt gct tta tac ttt gga aac agg aag cag ttg gaa gag 1872 Ala Thr Asp Leu Ala Leu Tyr Phe Gly Asn Arg Lys Gln Leu Glu Glu 610 615 620 atg tac cag acc gga tca cta aac ctt aat aat caa tca cat aga gac 1920 Met Tyr Gln Thr Gly Ser Leu Asn Leu Asn Asn Gln Ser His Arg Asp 625 630 635 640 cgt gta att ggt ttg atg atg act gcc tgt gac ctt tgt tct gtg aca 1968 Arg Val Ile Gly Leu Met Met Thr Ala Cys Asp Leu Cys Ser Val Thr 645 650 655 aaa ctg tgg ccc gtt aca aaa ttg acg gca aat gat ata tat gca gaa 2016 Lys Leu Trp Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Ala Glu 660 665 670 ttc tgg gct gag ggt gat gaa atg aag aaa ttg gga ata cag cct att 2064 Phe Trp Ala Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pro Ile 675 680 685 cct atg atg gac aga gac aag aag gat gaa gtc ccc caa ggc cag ctt 2112 Pro Met Met Asp Arg Asp Lys Lys Asp Glu Val Pro Gln Gly Gln Leu 690 695 700 ggg ttc tac aat gcc gtg gcc att ccc tgc tat aca acc ctt acc cag 2160 Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr Thr Thr Leu Thr Gln 705 710 715 720 atc ctc cct ccc acg gag cct ctt ctg aaa gca tgc agg gat aat ctc 2208 Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala Cys Arg Asp Asn Leu 725 730 735 agt cag tgg gag aag gtg att cga ggg gag gag act gca acc tgg att 2256 Ser Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala Thr Trp Ile 740 745 750 tca tcc cca tcc gtg gct cag aag gca gct gca tct gaa gat 2298 Ser Ser Pro Ser Val Ala Gln Lys Ala Ala Ala Ser Glu Asp 755 760 765 <210> SEQ ID NO 2 <211> LENGTH: 766 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <221> NAME/KEY: misc_feature <222> LOCATION: (290) <223> OTHER INFORMATION: The amino acid is either Pro or Leu <400> SEQUENCE: 2 Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val 1 5 10 15 Leu Asp Glu Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys 20 25 30 Trp Leu Lys Arg Lys Asn Asn Lys Ser Glu Asp Glu Ser Ala Pro Lys 35 40 45 Glu Val Ser Arg Tyr Gln Asp Thr Asn Met Gln Gly Val Val Tyr Glu 50 55 60 Leu Asn Ser Tyr Ile Glu Gln Arg Leu Asp Thr Gly Gly Asp Asn Gln 65 70 75 80 Leu Leu Leu Tyr Glu Leu Ser Ser Ile Ile Lys Ile Ala Thr Lys Ala 85 90 95 Asp Gly Phe Ala Leu Tyr Phe Leu Gly Glu Cys Asn Asn Ser Leu Cys 100 105 110 Ile Phe Thr Pro Pro Gly Ile Lys Glu Gly Lys Pro Arg Leu Ile Pro 115 120 125 Ala Gly Pro Ile Thr Gln Gly Thr Thr Val Ser Ala Tyr Val Ala Lys 130 135 140 Ser Arg Lys Thr Leu Leu Val Glu Asp Ile Leu Gly Asp Glu Arg Phe 145 150 155 160 Pro Arg Gly Thr Gly Leu Glu Ser Gly Thr Arg Ile Gln Ser Val Leu 165 170 175 Cys Leu Pro Ile Val Thr Ala Ile Gly Asp Leu Ile Gly Ile Leu Glu 180 185 190 Leu Tyr Arg His Trp Gly Lys Glu Ala Phe Cys Leu Ser His Gln Glu 195 200 205 Val Ala Thr Ala Asn Leu Ala Trp Ala Ser Val Ala Ile His Gln Val 210 215 220 Gln Val Cys Arg Gly Leu Ala Lys Gln Thr Glu Leu Asn Asp Phe Leu 225 230 235 240 Leu Asp Val Ser Lys Thr Tyr Phe Asp Asn Ile Val Ala Ile Asp Ser 245 250 255 Leu Leu Glu His Ile Met Ile Tyr Ala Lys Asn Leu Val Asn Ala Asp 260 265 270 Arg Cys Ala Leu Phe Gln Val Asp His Lys Asn Lys Glu Leu Tyr Ser 275 280 285 Asp Xaa Phe Asp Ile Gly Glu Glu Lys Glu Gly Lys Pro Val Phe Lys 290 295 300 Lys Thr Lys Glu Ile Arg Phe Ser Ile Glu Lys Gly Ile Ala Gly Gln 305 310 315 320 Val Ala Arg Thr Gly Glu Val Leu Asn Ile Pro Asp Ala Tyr Ala Asp 325 330 335 Pro Arg Phe Asn Arg Glu Val Asp Leu Tyr Thr Gly Tyr Thr Thr Arg 340 345 350 Asn Ile Leu Cys Met Pro Ile Val Ser Arg Gly Ser Val Ile Gly Val 355 360 365 Val Gln Met Val Asn Lys Ile Ser Gly Ser Ala Phe Ser Lys Thr Asp 370 375 380 Glu Asn Asn Phe Lys Met Phe Ala Val Phe Cys Ala Leu Ala Leu His 385 390 395 400 Cys Ala Asn Met Tyr His Arg Ile Arg His Ser Glu Cys Ile Tyr Arg 405 410 415 Val Thr Met Glu Lys Leu Ser Tyr His Ser Ile Cys Thr Ser Glu Glu 420 425 430 Trp Gln Gly Leu Met Gln Phe Thr Leu Pro Val Arg Leu Cys Lys Glu 435 440 445 Ile Glu Leu Phe His Phe Asp Ile Gly Pro Phe Glu Asn Met Trp Pro 450 455 460 Gly Ile Phe Val Tyr Met Val His Arg Ser Cys Gly Thr Ser Cys Phe 465 470 475 480 Glu Leu Glu Lys Leu Cys Arg Phe Ile Met Ser Val Lys Lys Asn Tyr 485 490 495 Arg Arg Val Pro Tyr His Asn Trp Lys His Ala Val Thr Val Ala His 500 505 510 Cys Met Tyr Ala Ile Leu Gln Asn Asn His Thr Leu Phe Thr Asp Leu 515 520 525 Glu Arg Lys Gly Leu Leu Ile Ala Cys Leu Cys His Asp Leu Asp His 530 535 540 Arg Gly Phe Ser Asn Ser Tyr Leu Gln Lys Phe Asp His Pro Leu Ala 545 550 555 560 Ala Leu Tyr Ser Thr Ser Thr Met Glu Gln His His Phe Ser Gln Thr 565 570 575 Val Ser Ile Leu Gln Leu Glu Gly His Asn Ile Phe Ser Thr Leu Ser 580 585 590 Ser Ser Glu Tyr Glu Gln Val Leu Glu Ile Ile Arg Lys Ala Ile Ile 595 600 605 Ala Thr Asp Leu Ala Leu Tyr Phe Gly Asn Arg Lys Gln Leu Glu Glu 610 615 620 Met Tyr Gln Thr Gly Ser Leu Asn Leu Asn Asn Gln Ser His Arg Asp 625 630 635 640 Arg Val Ile Gly Leu Met Met Thr Ala Cys Asp Leu Cys Ser Val Thr 645 650 655 Lys Leu Trp Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Ala Glu 660 665 670 Phe Trp Ala Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pro Ile 675 680 685 Pro Met Met Asp Arg Asp Lys Lys Asp Glu Val Pro Gln Gly Gln Leu 690 695 700 Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr Thr Thr Leu Thr Gln 705 710 715 720 Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala Cys Arg Asp Asn Leu 725 730 735 Ser Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala Thr Trp Ile 740 745 750 Ser Ser Pro Ser Val Ala Gln Lys Ala Ala Ala Ser Glu Asp 755 760 765 <210> SEQ ID NO 3 <211> LENGTH: 4389 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (3)..(2411) <400> SEQUENCE: 3 gc ttc gcc ctc gcc gcc gcg gcc gcg ctg ctc ttc ggc tcc gac atg 47 Phe Ala Leu Ala Ala Ala Ala Ala Leu Leu Phe Gly Ser Asp Met 1 5 10 15 gaa gat gga cct tct aat aat gcg agc tgc ttc cga agg ctg acc gag 95 Glu Asp Gly Pro Ser Asn Asn Ala Ser Cys Phe Arg Arg Leu Thr Glu 20 25 30 tgc ttc ctg agc ccc agt ttg aca gat gaa aaa gtg aag gca tat ctt 143 Cys Phe Leu Ser Pro Ser Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu 35 40 45 tct ctt cac ccc cag gta tta gat gaa ttt gta tct gaa agt gtt agt 191 Ser Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu Ser Val Ser 50 55 60 gca gag aca gta gag aaa tgg ctg aag agg aag aac aac aaa tca gaa 239 Ala Glu Thr Val Glu Lys Trp Leu Lys Arg Lys Asn Asn Lys Ser Glu 65 70 75 gat gaa tcg gct cct aag gaa gtc agc agg tac caa gat acg aat atg 287 Asp Glu Ser Ala Pro Lys Glu Val Ser Arg Tyr Gln Asp Thr Asn Met 80 85 90 95 cag gga gtt gta tat gaa cta aac agc tat ata gaa caa cgg ttg gac 335 Gln Gly Val Val Tyr Glu Leu Asn Ser Tyr Ile Glu Gln Arg Leu Asp 100 105 110 aca gga gga gac aac cag cta ctc ctc tat gaa ctg agc agc atc att 383 Thr Gly Gly Asp Asn Gln Leu Leu Leu Tyr Glu Leu Ser Ser Ile Ile 115 120 125 aaa ata gcc aca aaa gcc gat gga ttt gca ctg tat ttc ctt gga gag 431 Lys Ile Ala Thr Lys Ala Asp Gly Phe Ala Leu Tyr Phe Leu Gly Glu 130 135 140 tgc aat aat agc ctg tgt ata ttc acg cca cct ggg ata aag gaa gga 479 Cys Asn Asn Ser Leu Cys Ile Phe Thr Pro Pro Gly Ile Lys Glu Gly 145 150 155 aaa ccc cgc ctc atc cct gct ggg ccc atc act cag ggc acc acc gtc 527 Lys Pro Arg Leu Ile Pro Ala Gly Pro Ile Thr Gln Gly Thr Thr Val 160 165 170 175 tct gct tat gtg gcc aag tcc agg aaa aca ctg cta gta gaa gac atc 575 Ser Ala Tyr Val Ala Lys Ser Arg Lys Thr Leu Leu Val Glu Asp Ile 180 185 190 ctt gga gat gaa cga ttt cca aga ggt act gga ctg gaa tca ggg act 623 Leu Gly Asp Glu Arg Phe Pro Arg Gly Thr Gly Leu Glu Ser Gly Thr 195 200 205 cgt atc cag tct gtt ctt tgc tta cca att gtc act gca att ggt gac 671 Arg Ile Gln Ser Val Leu Cys Leu Pro Ile Val Thr Ala Ile Gly Asp 210 215 220 ttg att ggt att ctc gag ctg tat cgg cac tgg ggc aaa gaa gcc ttc 719 Leu Ile Gly Ile Leu Glu Leu Tyr Arg His Trp Gly Lys Glu Ala Phe 225 230 235 tgt ctt agt cac cag gag gtt gca aca gca aat ctt gcc tgg gct tca 767 Cys Leu Ser His Gln Glu Val Ala Thr Ala Asn Leu Ala Trp Ala Ser 240 245 250 255 gta gca ata cat cag gtg cag gta tgc aga ggc ctt gcc aaa cag aca 815 Val Ala Ile His Gln Val Gln Val Cys Arg Gly Leu Ala Lys Gln Thr 260 265 270 gaa ttg aat gac ttc cta ctc gac gta tca aaa aca tat ttt gat aac 863 Glu Leu Asn Asp Phe Leu Leu Asp Val Ser Lys Thr Tyr Phe Asp Asn 275 280 285 ata gtt gca ata gat tct cta ctt gaa cac ata atg ata tat gca aaa 911 Ile Val Ala Ile Asp Ser Leu Leu Glu His Ile Met Ile Tyr Ala Lys 290 295 300 aac ctg gtg aat gcc gat cgt tgt gca ctt ttc cag gtg gac cat aag 959 Asn Leu Val Asn Ala Asp Arg Cys Ala Leu Phe Gln Val Asp His Lys 305 310 315 aac aag gag tta tat tca gac cct ttt gat att gga gag gaa aag gaa 1007 Asn Lys Glu Leu Tyr Ser Asp Pro Phe Asp Ile Gly Glu Glu Lys Glu 320 325 330 335 gga aaa cct gtc ttc aag aag acc aaa gag ata aga ttt tca att gag 1055 Gly Lys Pro Val Phe Lys Lys Thr Lys Glu Ile Arg Phe Ser Ile Glu 340 345 350 aaa gga att gct ggc caa gta gca aga aca ggg gaa gtc ctg aac att 1103 Lys Gly Ile Ala Gly Gln Val Ala Arg Thr Gly Glu Val Leu Asn Ile 355 360 365 cca gat gcc tat gca gac cca cgc ttt aac aga gaa gta gac ttg tac 1151 Pro Asp Ala Tyr Ala Asp Pro Arg Phe Asn Arg Glu Val Asp Leu Tyr 370 375 380 aca ggc tac acc acg cgg aac atc ctg tgc atg ccc atc gtc agc cga 1199 Thr Gly Tyr Thr Thr Arg Asn Ile Leu Cys Met Pro Ile Val Ser Arg 385 390 395 ggc agc gtg ata ggt gtg gtg cag atg gtc aac aaa atc agt ggc agt 1247 Gly Ser Val Ile Gly Val Val Gln Met Val Asn Lys Ile Ser Gly Ser 400 405 410 415 gcc ttc tct aaa aca gat gaa aac aac ttc aaa atg ttt gcc gtc ttt 1295 Ala Phe Ser Lys Thr Asp Glu Asn Asn Phe Lys Met Phe Ala Val Phe 420 425 430 tgt gct tta gcc tta cac tgt gct aat atg tat cat aga att cgc cac 1343 Cys Ala Leu Ala Leu His Cys Ala Asn Met Tyr His Arg Ile Arg His 435 440 445 tca gag tgc att tac cgg gta acg atg gaa aag ctg tcc tac cat agc 1391 Ser Glu Cys Ile Tyr Arg Val Thr Met Glu Lys Leu Ser Tyr His Ser 450 455 460 att tgt act tca gaa gag tgg caa ggt ctc atg caa ttc acc ctt ccc 1439 Ile Cys Thr Ser Glu Glu Trp Gln Gly Leu Met Gln Phe Thr Leu Pro 465 470 475 gtg cgt ctc tgc aaa gaa att gaa tta ttc cac ttt gac att ggt cct 1487 Val Arg Leu Cys Lys Glu Ile Glu Leu Phe His Phe Asp Ile Gly Pro 480 485 490 495 ttt gaa aac atg tgg cct gga att ttt gtc tac atg gtt cat cgg tcc 1535 Phe Glu Asn Met Trp Pro Gly Ile Phe Val Tyr Met Val His Arg Ser 500 505 510 tgt ggg aca tcc tgc ttt gag ctt gaa aag ttg tgt cgt ttt att atg 1583 Cys Gly Thr Ser Cys Phe Glu Leu Glu Lys Leu Cys Arg Phe Ile Met 515 520 525 tct gtg aag aag aac tat cgg cgg gtt cct tat cac aac tgg aag cat 1631 Ser Val Lys Lys Asn Tyr Arg Arg Val Pro Tyr His Asn Trp Lys His 530 535 540 gcg gtc act gta gca cac tgc atg tat gcc ata ctt cag aac aat cac 1679 Ala Val Thr Val Ala His Cys Met Tyr Ala Ile Leu Gln Asn Asn His 545 550 555 acg ctt ttc aca gac ctt gag cgc aaa gga ctg ctg att gcg tgt ctg 1727 Thr Leu Phe Thr Asp Leu Glu Arg Lys Gly Leu Leu Ile Ala Cys Leu 560 565 570 575 tgt cat gac ctg gac cac agg ggc ttc agt aac agc tac ctg cag aag 1775 Cys His Asp Leu Asp His Arg Gly Phe Ser Asn Ser Tyr Leu Gln Lys 580 585 590 ttc gac cac cct ctg gcc gct ctc tac tcc act tcc acc atg gag cag 1823 Phe Asp His Pro Leu Ala Ala Leu Tyr Ser Thr Ser Thr Met Glu Gln 595 600 605 cac cac ttc tcc cag act gtg tcc atc ctc cag ttg gaa ggg cac aat 1871 His His Phe Ser Gln Thr Val Ser Ile Leu Gln Leu Glu Gly His Asn 610 615 620 atc ttc tcc act ctg agc tcc agt gaa tat gag cag gtg ctt gag atc 1919 Ile Phe Ser Thr Leu Ser Ser Ser Glu Tyr Glu Gln Val Leu Glu Ile 625 630 635 atc cgc aaa gcc atc att gcc aca gac ctt gct tta tac ttt gga aac 1967 Ile Arg Lys Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr Phe Gly Asn 640 645 650 655 agg aag cag ttg gaa gag atg tac cag acc gga tca cta aac ctt aat 2015 Arg Lys Gln Leu Glu Glu Met Tyr Gln Thr Gly Ser Leu Asn Leu Asn 660 665 670 aat caa tca cat aga gac cgt gta att ggt ttg atg atg act gcc tgt 2063 Asn Gln Ser His Arg Asp Arg Val Ile Gly Leu Met Met Thr Ala Cys 675 680 685 gac ctt tgt tct gtg aca aaa ctg tgg ccc gtt aca aaa ttg acg gca 2111 Asp Leu Cys Ser Val Thr Lys Leu Trp Pro Val Thr Lys Leu Thr Ala 690 695 700 aat gat ata tat gca gaa ttc tgg gct gag ggt gat gaa atg aag aaa 2159 Asn Asp Ile Tyr Ala Glu Phe Trp Ala Glu Gly Asp Glu Met Lys Lys 705 710 715 ttg gga ata cag cct att cct atg atg gac aga gac aag aag gat gaa 2207 Leu Gly Ile Gln Pro Ile Pro Met Met Asp Arg Asp Lys Lys Asp Glu 720 725 730 735 gtc ccc caa ggc cag ctt ggg ttc tac aat gcc gtg gcc att ccc tgc 2255 Val Pro Gln Gly Gln Leu Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys 740 745 750 tat aca acc ctt acc cag atc ctc cct ccc acg gag cct ctt ctg aaa 2303 Tyr Thr Thr Leu Thr Gln Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys 755 760 765 gca tgc agg gat aat ctc agt cag tgg gag aag gtg att cga ggg gag 2351 Ala Cys Arg Asp Asn Leu Ser Gln Trp Glu Lys Val Ile Arg Gly Glu 770 775 780 gag act gca acc tgg att tca tcc cca tcc gtg gct cag aag gca gct 2399 Glu Thr Ala Thr Trp Ile Ser Ser Pro Ser Val Ala Gln Lys Ala Ala 785 790 795 gca tct gaa gat tgagcactgg tcaccctgac acgctgtccc acctacagat 2451 Ala Ser Glu Asp 800 cctcatcttg cttctttgac attcttttcc tttttttggg gggggtgggg ggaacctgca 2511 cctggtaact ggggtgcaaa cctcttcaag aaggtaacat caaataaata agtcaagcag 2571 aggacttcct gccaatctct tctgtgaggc atcatagaca ctgagcaacc aggaccaccc 2631 ccacgttcag aaatcagctg gccaagtgac tccatttgac ttgcaaacca gccttttcta 2691 ataggctaat attgctgagg ccttaaagga aatggacaaa aattatccag aaggggtact 2751 tttccattgt atctttctaa taagggttta aaatggtact attatggtat tgtacttggg 2811 ctttaacatc aatgttgctt tgatgttgtt ggatataaat aggaattttt acacattact 2871 attgtgaatg gtgaatgttc atgtatgacc tacttgtaat taacttgagt tgtagtccac 2931 agcctcagga caaatgtcgt tgaggttaca gagtaagaaa tgatggcaaa acgtcaaact 2991 cttatttcag agcttcatga atttagttag actaaacata attctttaag ttcaacctaa 3051 agggctgaga tcaataaatt taacactaga cgaagtagac ttcctgtctt tttgagaaga 3111 gatgaggtat atgttacaat aaatctcaga acttcaagta gcagttcaaa agatgtcagt 3171 ttttaaaatt gtttttgttg ttgtcttggc agttttactg aaccctttgc ataaagaaca 3231 aaataaaagc tcggcattgt aattttttta atggacaagt cttatggata cgaagggtac 3291 atttttcata atgattcctt tatattttca ctttgtgtca ttgcagaatt ttagactctc 3351 attcacaatg aaaagtttat tttaaacatt gtttaattaa aataccatac agttctcttt 3411 taaacatcaa accataaaaa gtgtattttg taattttact ctgacctgcc gcagtcacct 3471 ctcacttatc tcttccacgt actgcacggt cgtatttcat gagctttctg tccatagcac 3531 agaaacagag cagaaagtag tacaatcatg ttggaccttc tttctgttct ctttactctt 3591 ctcacagatc agatcactcc atagaagcct gtgggtttcg atggtttctt ctatacacct 3651 ttttggttga ccagtattac tatacaatgt aagtgtttta aaaaatacga aagtaatact 3711 ctgcacccct tcctacaaag atgataaagc agtcacttct ggcgcatttt aataatttaa 3771 agatttttag tgcaatggca cggtaacctc caaacctgaa ttagacagag actcactcag 3831 gaagtgacag gcccatcata tcaaataact tattcacttt tcatgtggca ggaaactgga 3891 atatcgcttt taataaaatg gaaaaatatg cttctacata tttaccacca taggcgtttt 3951 gttcatatga gcctggtttg tgcaaaatta aatcagaggc ttctacaaca tggtttattt 4011 atgttgtagc aaagttggct ctacataaac attgttctta ttttaaaatt aacactatgt 4071 gttcagtttt cttgtgggct tctgaaagtt gccatcttcc ctccgtggag ctccatttgc 4131 tattttcatt atacactatg aggtaaaatg taataacaaa agagagagaa gtaccactgt 4191 ggctagatat atacacacac atatatatat ggatggatgt aatatatgta gaacacacac 4251 atagatgtat ataggataca cactcatgta tgtaaacgta tacatatgtg tatatatgat 4311 acatacacat acacacacac gagagacaga aggaaagaga ggaagagaga agcaaacatg 4371 taggaaaaaa tataaatc 4389 <210> SEQ ID NO 4 <211> LENGTH: 803 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Phe Ala Leu Ala Ala Ala Ala Ala Leu Leu Phe Gly Ser Asp Met Glu 1 5 10 15 Asp Gly Pro Ser Asn Asn Ala Ser Cys Phe Arg Arg Leu Thr Glu Cys 20 25 30 Phe Leu Ser Pro Ser Leu Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser 35 40 45 Leu His Pro Gln Val Leu Asp Glu Phe Val Ser Glu Ser Val Ser Ala 50 55 60 Glu Thr Val Glu Lys Trp Leu Lys Arg Lys Asn Asn Lys Ser Glu Asp 65 70 75 80 Glu Ser Ala Pro Lys Glu Val Ser Arg Tyr Gln Asp Thr Asn Met Gln 85 90 95 Gly Val Val Tyr Glu Leu Asn Ser Tyr Ile Glu Gln Arg Leu Asp Thr 100 105 110 Gly Gly Asp Asn Gln Leu Leu Leu Tyr Glu Leu Ser Ser Ile Ile Lys 115 120 125 Ile Ala Thr Lys Ala Asp Gly Phe Ala Leu Tyr Phe Leu Gly Glu Cys 130 135 140 Asn Asn Ser Leu Cys Ile Phe Thr Pro Pro Gly Ile Lys Glu Gly Lys 145 150 155 160 Pro Arg Leu Ile Pro Ala Gly Pro Ile Thr Gln Gly Thr Thr Val Ser 165 170 175 Ala Tyr Val Ala Lys Ser Arg Lys Thr Leu Leu Val Glu Asp Ile Leu 180 185 190 Gly Asp Glu Arg Phe Pro Arg Gly Thr Gly Leu Glu Ser Gly Thr Arg 195 200 205 Ile Gln Ser Val Leu Cys Leu Pro Ile Val Thr Ala Ile Gly Asp Leu 210 215 220 Ile Gly Ile Leu Glu Leu Tyr Arg His Trp Gly Lys Glu Ala Phe Cys 225 230 235 240 Leu Ser His Gln Glu Val Ala Thr Ala Asn Leu Ala Trp Ala Ser Val 245 250 255 Ala Ile His Gln Val Gln Val Cys Arg Gly Leu Ala Lys Gln Thr Glu 260 265 270 Leu Asn Asp Phe Leu Leu Asp Val Ser Lys Thr Tyr Phe Asp Asn Ile 275 280 285 Val Ala Ile Asp Ser Leu Leu Glu His Ile Met Ile Tyr Ala Lys Asn 290 295 300 Leu Val Asn Ala Asp Arg Cys Ala Leu Phe Gln Val Asp His Lys Asn 305 310 315 320 Lys Glu Leu Tyr Ser Asp Pro Phe Asp Ile Gly Glu Glu Lys Glu Gly 325 330 335 Lys Pro Val Phe Lys Lys Thr Lys Glu Ile Arg Phe Ser Ile Glu Lys 340 345 350 Gly Ile Ala Gly Gln Val Ala Arg Thr Gly Glu Val Leu Asn Ile Pro 355 360 365 Asp Ala Tyr Ala Asp Pro Arg Phe Asn Arg Glu Val Asp Leu Tyr Thr 370 375 380 Gly Tyr Thr Thr Arg Asn Ile Leu Cys Met Pro Ile Val Ser Arg Gly 385 390 395 400 Ser Val Ile Gly Val Val Gln Met Val Asn Lys Ile Ser Gly Ser Ala 405 410 415 Phe Ser Lys Thr Asp Glu Asn Asn Phe Lys Met Phe Ala Val Phe Cys 420 425 430 Ala Leu Ala Leu His Cys Ala Asn Met Tyr His Arg Ile Arg His Ser 435 440 445 Glu Cys Ile Tyr Arg Val Thr Met Glu Lys Leu Ser Tyr His Ser Ile 450 455 460 Cys Thr Ser Glu Glu Trp Gln Gly Leu Met Gln Phe Thr Leu Pro Val 465 470 475 480 Arg Leu Cys Lys Glu Ile Glu Leu Phe His Phe Asp Ile Gly Pro Phe 485 490 495 Glu Asn Met Trp Pro Gly Ile Phe Val Tyr Met Val His Arg Ser Cys 500 505 510 Gly Thr Ser Cys Phe Glu Leu Glu Lys Leu Cys Arg Phe Ile Met Ser 515 520 525 Val Lys Lys Asn Tyr Arg Arg Val Pro Tyr His Asn Trp Lys His Ala 530 535 540 Val Thr Val Ala His Cys Met Tyr Ala Ile Leu Gln Asn Asn His Thr 545 550 555 560 Leu Phe Thr Asp Leu Glu Arg Lys Gly Leu Leu Ile Ala Cys Leu Cys 565 570 575 His Asp Leu Asp His Arg Gly Phe Ser Asn Ser Tyr Leu Gln Lys Phe 580 585 590 Asp His Pro Leu Ala Ala Leu Tyr Ser Thr Ser Thr Met Glu Gln His 595 600 605 His Phe Ser Gln Thr Val Ser Ile Leu Gln Leu Glu Gly His Asn Ile 610 615 620 Phe Ser Thr Leu Ser Ser Ser Glu Tyr Glu Gln Val Leu Glu Ile Ile 625 630 635 640 Arg Lys Ala Ile Ile Ala Thr Asp Leu Ala Leu Tyr Phe Gly Asn Arg 645 650 655 Lys Gln Leu Glu Glu Met Tyr Gln Thr Gly Ser Leu Asn Leu Asn Asn 660 665 670 Gln Ser His Arg Asp Arg Val Ile Gly Leu Met Met Thr Ala Cys Asp 675 680 685 Leu Cys Ser Val Thr Lys Leu Trp Pro Val Thr Lys Leu Thr Ala Asn 690 695 700 Asp Ile Tyr Ala Glu Phe Trp Ala Glu Gly Asp Glu Met Lys Lys Leu 705 710 715 720 Gly Ile Gln Pro Ile Pro Met Met Asp Arg Asp Lys Lys Asp Glu Val 725 730 735 Pro Gln Gly Gln Leu Gly Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr 740 745 750 Thr Thr Leu Thr Gln Ile Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala 755 760 765 Cys Arg Asp Asn Leu Ser Gln Trp Glu Lys Val Ile Arg Gly Glu Glu 770 775 780 Thr Ala Thr Trp Ile Ser Ser Pro Ser Val Ala Gln Lys Ala Ala Ala 785 790 795 800 Ser Glu Asp <210> SEQ ID NO 5 <211> LENGTH: 3195 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (67)..(2403) <400> SEQUENCE: 5 catccacaga gatgttacag ttgaagagat gggggtagag aagactttga aggaaaagaa 60 tgtaga atg agg ata gaa gag agg aaa tcc caa cat tta aca ggt ttg 108 Met Arg Ile Glu Glu Arg Lys Ser Gln His Leu Thr Gly Leu 1 5 10 aca gat gaa aaa gtg aag gca tat ctt tct ctt cac ccc cag gta tta 156 Thr Asp Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val Leu 15 20 25 30 gat gaa ttt gta tct gaa agt gtt agt gca gag aca gta gag aaa tgg 204 Asp Glu Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys Trp 35 40 45 ctg aag agg aag aac aac aaa tca gaa gat gaa tcg gct cct aag gaa 252 Leu Lys Arg Lys Asn Asn Lys Ser Glu Asp Glu Ser Ala Pro Lys Glu 50 55 60 gtc agc agg tac caa gat acg aat atg cag gga gtt gta tat gaa cta 300 Val Ser Arg Tyr Gln Asp Thr Asn Met Gln Gly Val Val Tyr Glu Leu 65 70 75 aac agc tat ata gaa caa cgg ttg gac aca gga gga gac aac cag cta 348 Asn Ser Tyr Ile Glu Gln Arg Leu Asp Thr Gly Gly Asp Asn Gln Leu 80 85 90 ctc ctc tat gaa ctg agc agc atc att aaa ata gcc aca aaa gcc gat 396 Leu Leu Tyr Glu Leu Ser Ser Ile Ile Lys Ile Ala Thr Lys Ala Asp 95 100 105 110 gga ttt gca ctg tat ttc ctt gga gag tgc aat aat agc ctg tgt ata 444 Gly Phe Ala Leu Tyr Phe Leu Gly Glu Cys Asn Asn Ser Leu Cys Ile 115 120 125 ttc acg cca cct ggg ata aag gaa gga aaa ccc cgc ctc atc cct gct 492 Phe Thr Pro Pro Gly Ile Lys Glu Gly Lys Pro Arg Leu Ile Pro Ala 130 135 140 ggg ccc atc act cag ggc acc acc gtc tct gct tat gtg gcc aag tcc 540 Gly Pro Ile Thr Gln Gly Thr Thr Val Ser Ala Tyr Val Ala Lys Ser 145 150 155 agg aaa aca ctg cta gta gaa gac atc ctt gga gat gaa cga ttt cca 588 Arg Lys Thr Leu Leu Val Glu Asp Ile Leu Gly Asp Glu Arg Phe Pro 160 165 170 aga ggt act gga ctg gaa tca ggg act cgt atc cag tct gtt ctt tgc 636 Arg Gly Thr Gly Leu Glu Ser Gly Thr Arg Ile Gln Ser Val Leu Cys 175 180 185 190 tta cca att gtc act gca att ggt gac ttg att ggt att ctc gag ctg 684 Leu Pro Ile Val Thr Ala Ile Gly Asp Leu Ile Gly Ile Leu Glu Leu 195 200 205 tat cgg cac tgg ggc aaa gaa gcc ttc tgt ctt agt cac cag gag gtt 732 Tyr Arg His Trp Gly Lys Glu Ala Phe Cys Leu Ser His Gln Glu Val 210 215 220 gca aca gca aat ctt gcc tgg gct tca gta gca ata cat cag gtg cag 780 Ala Thr Ala Asn Leu Ala Trp Ala Ser Val Ala Ile His Gln Val Gln 225 230 235 gta tgc aga ggc ctt gcc aaa cag aca gaa ttg aat gac ttc cta ctc 828 Val Cys Arg Gly Leu Ala Lys Gln Thr Glu Leu Asn Asp Phe Leu Leu 240 245 250 gac gta tca aaa aca tat ttt gat aac ata gtt gca ata gat tct cta 876 Asp Val Ser Lys Thr Tyr Phe Asp Asn Ile Val Ala Ile Asp Ser Leu 255 260 265 270 ctt gaa cac ata atg ata tat gca aaa aac ctg gtg aat gcc gat cgt 924 Leu Glu His Ile Met Ile Tyr Ala Lys Asn Leu Val Asn Ala Asp Arg 275 280 285 tgt gca ctt ttc cag gtg gac cat aag aac aag gag tta tat tca gac 972 Cys Ala Leu Phe Gln Val Asp His Lys Asn Lys Glu Leu Tyr Ser Asp 290 295 300 ctt ttt gat att gga gag gaa aag gaa gga aaa cct gtc ttc aag aag 1020 Leu Phe Asp Ile Gly Glu Glu Lys Glu Gly Lys Pro Val Phe Lys Lys 305 310 315 acc aaa gag ata aga ttt tca att gag aaa gga att gct ggc caa gta 1068 Thr Lys Glu Ile Arg Phe Ser Ile Glu Lys Gly Ile Ala Gly Gln Val 320 325 330 gca aga aca ggg gaa gtc ctg aac att cca gat gcc tat gca gac cca 1116 Ala Arg Thr Gly Glu Val Leu Asn Ile Pro Asp Ala Tyr Ala Asp Pro 335 340 345 350 cgc ttt aac aga gaa gta gac ttg tac aca ggc tac acc acg cgg aac 1164 Arg Phe Asn Arg Glu Val Asp Leu Tyr Thr Gly Tyr Thr Thr Arg Asn 355 360 365 atc ctg tgc atg ccc atc gtc agc cga ggc agc gtg ata ggt gtg gtg 1212 Ile Leu Cys Met Pro Ile Val Ser Arg Gly Ser Val Ile Gly Val Val 370 375 380 cag atg gtc aac aaa atc agt ggc agt gcc ttc tct aaa aca gat gaa 1260 Gln Met Val Asn Lys Ile Ser Gly Ser Ala Phe Ser Lys Thr Asp Glu 385 390 395 aac aac ttc aaa atg ttt gcc gtc ttt tgt gct tta gcc tta cac tgt 1308 Asn Asn Phe Lys Met Phe Ala Val Phe Cys Ala Leu Ala Leu His Cys 400 405 410 gct aat atg tat cat aga att cgc cac tca gag tgc att tac cgg gta 1356 Ala Asn Met Tyr His Arg Ile Arg His Ser Glu Cys Ile Tyr Arg Val 415 420 425 430 acg atg gaa aag ctg tcc tac cat agc att tgt act tca gaa gag tgg 1404 Thr Met Glu Lys Leu Ser Tyr His Ser Ile Cys Thr Ser Glu Glu Trp 435 440 445 caa ggt ctc atg caa ttc acc ctt ccc gtg cgt ctc tgc aaa gaa att 1452 Gln Gly Leu Met Gln Phe Thr Leu Pro Val Arg Leu Cys Lys Glu Ile 450 455 460 gaa tta ttc cac ttt gac att ggt cct ttt gaa aac atg tgg cct gga 1500 Glu Leu Phe His Phe Asp Ile Gly Pro Phe Glu Asn Met Trp Pro Gly 465 470 475 att ttt gtc tac atg gtt cat cgg tcc tgt ggg aca tcc tgc ttt gag 1548 Ile Phe Val Tyr Met Val His Arg Ser Cys Gly Thr Ser Cys Phe Glu 480 485 490 ctt gaa aag ttg tgt cgt ttt att atg tct gtg aag aag aac tat cgg 1596 Leu Glu Lys Leu Cys Arg Phe Ile Met Ser Val Lys Lys Asn Tyr Arg 495 500 505 510 cgg gtt cct tat cac aac tgg aag cat gcg gtc act gta gca cac tgc 1644 Arg Val Pro Tyr His Asn Trp Lys His Ala Val Thr Val Ala His Cys 515 520 525 atg tat gcc ata ctt cag aac aat cac acg ctt ttc aca gac ctt gag 1692 Met Tyr Ala Ile Leu Gln Asn Asn His Thr Leu Phe Thr Asp Leu Glu 530 535 540 cgc aaa gga ctg ctg att gcg tgt ctg tgt cat gac ctg gac cac agg 1740 Arg Lys Gly Leu Leu Ile Ala Cys Leu Cys His Asp Leu Asp His Arg 545 550 555 ggc ttc agt aac agc tac ctg cag aag ttc gac cac cct ctg gcc gct 1788 Gly Phe Ser Asn Ser Tyr Leu Gln Lys Phe Asp His Pro Leu Ala Ala 560 565 570 ctc tac tcc act tcc acc atg gag cag cac cac ttc tcc cag act gtg 1836 Leu Tyr Ser Thr Ser Thr Met Glu Gln His His Phe Ser Gln Thr Val 575 580 585 590 tcc atc ctc cag ttg gaa ggg cac aat atc ttc tcc act ctg agc tcc 1884 Ser Ile Leu Gln Leu Glu Gly His Asn Ile Phe Ser Thr Leu Ser Ser 595 600 605 agt gaa tat gag cag gtg ctt gag atc atc cgc aaa gcc atc att gcc 1932 Ser Glu Tyr Glu Gln Val Leu Glu Ile Ile Arg Lys Ala Ile Ile Ala 610 615 620 aca gac ctt gct tta tac ttt gga aac agg aag cag ttg gaa gag atg 1980 Thr Asp Leu Ala Leu Tyr Phe Gly Asn Arg Lys Gln Leu Glu Glu Met 625 630 635 tac cag acc gga tca cta aac ctt aat aat caa tca cat aga gac cgt 2028 Tyr Gln Thr Gly Ser Leu Asn Leu Asn Asn Gln Ser His Arg Asp Arg 640 645 650 gta att ggt ttg atg atg act gcc tgt gac ctt tgt tct gtg aca aaa 2076 Val Ile Gly Leu Met Met Thr Ala Cys Asp Leu Cys Ser Val Thr Lys 655 660 665 670 ctg tgg ccc gtt aca aaa ttg acg gca aat gat ata tat gca gaa ttc 2124 Leu Trp Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Ala Glu Phe 675 680 685 tgg gct gag ggt gat gaa atg aag aaa ttg gga ata cag cct att cct 2172 Trp Ala Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pro Ile Pro 690 695 700 atg atg gac aga gac aag aag gat gaa gtc ccc caa ggc cag ctt ggg 2220 Met Met Asp Arg Asp Lys Lys Asp Glu Val Pro Gln Gly Gln Leu Gly 705 710 715 ttc tac aat gcc gtg gcc att ccc tgc tat aca acc ctt acc cag atc 2268 Phe Tyr Asn Ala Val Ala Ile Pro Cys Tyr Thr Thr Leu Thr Gln Ile 720 725 730 ctc cct ccc acg gag cct ctt ctg aaa gca tgc agg gat aat ctc agt 2316 Leu Pro Pro Thr Glu Pro Leu Leu Lys Ala Cys Arg Asp Asn Leu Ser 735 740 745 750 cag tgg gag aag gtg att cga ggg gag gag act gca acc tgg att tca 2364 Gln Trp Glu Lys Val Ile Arg Gly Glu Glu Thr Ala Thr Trp Ile Ser 755 760 765 tcc cca tcc gtg gct cag aag gca gct gca tct gaa gat tgagcactgg 2413 Ser Pro Ser Val Ala Gln Lys Ala Ala Ala Ser Glu Asp 770 775 tcaccctgac acgctgtccc acctacagat cctcatcttg cttctttgac attcttttcc 2473 tttttttggg gggggtgggg ggaacctgca cctggtaact ggggtgcaaa cctcttcaag 2533 aaggtaacat caaataaata agtcaagcag aggacttcct ggaattccaa tcccaacact 2593 ttgggaggct gaggtgggtg gatcacctga ggtctagagt tcgagactgg actgggcaag 2653 atggtgaaac tctgtctcta ctaaaaatac aaaaatacaa aattagctgg gtgtggtggt 2713 tgcatgcctg tagttcggga ggctgaggta ggagaatcac ttgaacctgg ggggtggagg 2773 ctgaagtgag ccaaggtcgt gtcagtgcac tccagcctag acaacagaac aagactctgt 2833 ctcaaaaaaa aaaaaaagta tatcctacaa atgctaatta attttttccc actagctaat 2893 tggtttatga ataagaaaga tgttaaaaaa tgatgacaaa tgcagtcggt tacagtggct 2953 catgcctgtg atcccagcac tttgggaggc cgaggcgggt ggatcatgag gtcaagagat 3013 cgagaccatc ctggccaaca tggtgaaacc ccgtctctac tgaaaaaaaa aaaaaattag 3073 ctgggcgtgg tgtgcatagt ggtgtaattc cagctactct ggaggctgag gcaggagaat 3133 cgcttgaacc caggaggcag aggttgcagt gagccaggat ggtggaattc ctgcagcccg 3193 gg 3195 <210> SEQ ID NO 6 <211> LENGTH: 779 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6 Met Arg Ile Glu Glu Arg Lys Ser Gln His Leu Thr Gly Leu Thr Asp 1 5 10 15 Glu Lys Val Lys Ala Tyr Leu Ser Leu His Pro Gln Val Leu Asp Glu 20 25 30 Phe Val Ser Glu Ser Val Ser Ala Glu Thr Val Glu Lys Trp Leu Lys 35 40 45 Arg Lys Asn Asn Lys Ser Glu Asp Glu Ser Ala Pro Lys Glu Val Ser 50 55 60 Arg Tyr Gln Asp Thr Asn Met Gln Gly Val Val Tyr Glu Leu Asn Ser 65 70 75 80 Tyr Ile Glu Gln Arg Leu Asp Thr Gly Gly Asp Asn Gln Leu Leu Leu 85 90 95 Tyr Glu Leu Ser Ser Ile Ile Lys Ile Ala Thr Lys Ala Asp Gly Phe 100 105 110 Ala Leu Tyr Phe Leu Gly Glu Cys Asn Asn Ser Leu Cys Ile Phe Thr 115 120 125 Pro Pro Gly Ile Lys Glu Gly Lys Pro Arg Leu Ile Pro Ala Gly Pro 130 135 140 Ile Thr Gln Gly Thr Thr Val Ser Ala Tyr Val Ala Lys Ser Arg Lys 145 150 155 160 Thr Leu Leu Val Glu Asp Ile Leu Gly Asp Glu Arg Phe Pro Arg Gly 165 170 175 Thr Gly Leu Glu Ser Gly Thr Arg Ile Gln Ser Val Leu Cys Leu Pro 180 185 190 Ile Val Thr Ala Ile Gly Asp Leu Ile Gly Ile Leu Glu Leu Tyr Arg 195 200 205 His Trp Gly Lys Glu Ala Phe Cys Leu Ser His Gln Glu Val Ala Thr 210 215 220 Ala Asn Leu Ala Trp Ala Ser Val Ala Ile His Gln Val Gln Val Cys 225 230 235 240 Arg Gly Leu Ala Lys Gln Thr Glu Leu Asn Asp Phe Leu Leu Asp Val 245 250 255 Ser Lys Thr Tyr Phe Asp Asn Ile Val Ala Ile Asp Ser Leu Leu Glu 260 265 270 His Ile Met Ile Tyr Ala Lys Asn Leu Val Asn Ala Asp Arg Cys Ala 275 280 285 Leu Phe Gln Val Asp His Lys Asn Lys Glu Leu Tyr Ser Asp Leu Phe 290 295 300 Asp Ile Gly Glu Glu Lys Glu Gly Lys Pro Val Phe Lys Lys Thr Lys 305 310 315 320 Glu Ile Arg Phe Ser Ile Glu Lys Gly Ile Ala Gly Gln Val Ala Arg 325 330 335 Thr Gly Glu Val Leu Asn Ile Pro Asp Ala Tyr Ala Asp Pro Arg Phe 340 345 350 Asn Arg Glu Val Asp Leu Tyr Thr Gly Tyr Thr Thr Arg Asn Ile Leu 355 360 365 Cys Met Pro Ile Val Ser Arg Gly Ser Val Ile Gly Val Val Gln Met 370 375 380 Val Asn Lys Ile Ser Gly Ser Ala Phe Ser Lys Thr Asp Glu Asn Asn 385 390 395 400 Phe Lys Met Phe Ala Val Phe Cys Ala Leu Ala Leu His Cys Ala Asn 405 410 415 Met Tyr His Arg Ile Arg His Ser Glu Cys Ile Tyr Arg Val Thr Met 420 425 430 Glu Lys Leu Ser Tyr His Ser Ile Cys Thr Ser Glu Glu Trp Gln Gly 435 440 445 Leu Met Gln Phe Thr Leu Pro Val Arg Leu Cys Lys Glu Ile Glu Leu 450 455 460 Phe His Phe Asp Ile Gly Pro Phe Glu Asn Met Trp Pro Gly Ile Phe 465 470 475 480 Val Tyr Met Val His Arg Ser Cys Gly Thr Ser Cys Phe Glu Leu Glu 485 490 495 Lys Leu Cys Arg Phe Ile Met Ser Val Lys Lys Asn Tyr Arg Arg Val 500 505 510 Pro Tyr His Asn Trp Lys His Ala Val Thr Val Ala His Cys Met Tyr 515 520 525 Ala Ile Leu Gln Asn Asn His Thr Leu Phe Thr Asp Leu Glu Arg Lys 530 535 540 Gly Leu Leu Ile Ala Cys Leu Cys His Asp Leu Asp His Arg Gly Phe 545 550 555 560 Ser Asn Ser Tyr Leu Gln Lys Phe Asp His Pro Leu Ala Ala Leu Tyr 565 570 575 Ser Thr Ser Thr Met Glu Gln His His Phe Ser Gln Thr Val Ser Ile 580 585 590 Leu Gln Leu Glu Gly His Asn Ile Phe Ser Thr Leu Ser Ser Ser Glu 595 600 605 Tyr Glu Gln Val Leu Glu Ile Ile Arg Lys Ala Ile Ile Ala Thr Asp 610 615 620 Leu Ala Leu Tyr Phe Gly Asn Arg Lys Gln Leu Glu Glu Met Tyr Gln 625 630 635 640 Thr Gly Ser Leu Asn Leu Asn Asn Gln Ser His Arg Asp Arg Val Ile 645 650 655 Gly Leu Met Met Thr Ala Cys Asp Leu Cys Ser Val Thr Lys Leu Trp 660 665 670 Pro Val Thr Lys Leu Thr Ala Asn Asp Ile Tyr Ala Glu Phe Trp Ala 675 680 685 Glu Gly Asp Glu Met Lys Lys Leu Gly Ile Gln Pro Ile Pro Met Met 690 695 700 Asp Arg Asp Lys Lys Asp Glu Val Pro Gln Gly Gln Leu Gly Phe Tyr 705 710 715 720 Asn Ala Val Ala Ile Pro Cys Tyr Thr Thr Leu Thr Gln Ile Leu Pro 725 730 735 Pro Thr Glu Pro Leu Leu Lys Ala Cys Arg Asp Asn Leu Ser Gln Trp 740 745 750 Glu Lys Val Ile Arg Gly Glu Glu Thr Ala Thr Trp Ile Ser Ser Pro 755 760 765 Ser Val Ala Gln Lys Ala Ala Ala Ser Glu Asp 770 775 <210> SEQ ID NO 7 <211> LENGTH: 458 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 attcggcacg ggctgcggcc agagggtggt cgaacttctg caggtaactg ttactgagcc 60 cctgtggtcc aggtcatgac acagacacgc aatcagcagt cctttgcgct caaggtctgt 120 gaaaagcgtg tgattgttct gaagtatggc atacatgcag tgtgctacag tgaccgcatg 180 cttccagttg tgataaggaa cccgccgata gttcttcttc acagacataa taaaacgaca 240 caacttttca agctcaaagc aggatgtccc acaggcccga tgaaccatgt agacaaaaat 300 tccaggccac atgttttcaa aaggaccaat gtcaaagtgg aataattcaa tttctttggc 360 agagacgcac cgggaaaggg tgaatttgca tgagaccttt ggccactctt ctgaaagtac 420 aaatgctatg gtaggacagc tttttccgtc ggttaccc 458 <210> SEQ ID NO 8 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <221> NAME/KEY: misc_feature <222> LOCATION: (3) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (4) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (6) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (8) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (9) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (10) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (11) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (12) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (13) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (14) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (15) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (16) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (17) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (18) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (19) <223> OTHER INFORMATION: The amino acid is any amino acid <221> NAME/KEY: misc_feature <222> LOCATION: (20) <223> OTHER INFORMATION: The amino acid is any amino acid <400> SEQUENCE: 8 His Asp Xaa Xaa His Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Ala 20 <210> SEQ ID NO 9 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: primer <400> SEQUENCE: 9 ggaaacagct atgaccatg 19 <210> SEQ ID NO 10 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: primer <400> SEQUENCE: 10 actctccaag gaatacag 18 <210> SEQ ID NO 11 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 11 ctgtctctgc actaacac 18 <210> SEQ ID NO 12 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 12 ttggcaaggc ctctgcat 18 <210> SEQ ID NO 13 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 13 cctctatgaa ctgagcag 18 <210> SEQ ID NO 14 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 14 gaaggcactg ccactgat 18 <210> SEQ ID NO 15 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 15 tcgagctgta tcggcact 18 <210> SEQ ID NO 16 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 16 agcgtgtgat tgttctgaa 19 <210> SEQ ID NO 17 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 17 tgctggccaa gtagcaag 18 <210> SEQ ID NO 18 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 18 aaggtcacag gcagtcat 18 <210> SEQ ID NO 19 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 19 gaagagtggc aaggtctc 18 <210> SEQ ID NO 20 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 20 tcatgacctg gaccaccag 19 <210> SEQ ID NO 21 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 21 ccttcttgaa gaggtttgc 19 <210> SEQ ID NO 22 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 22 atgactgcct gtgacctt 18 <210> SEQ ID NO 23 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 23 ctgctataca acccttacc 19 <210> SEQ ID NO 24 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 24 gctaatattg ctgaggcc 18 <210> SEQ ID NO 25 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 25 taagtgagag gtgactgc 18 <210> SEQ ID NO 26 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 26 cctaaagggc tgagatca 18 <210> SEQ ID NO 27 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 27 cgcagtcacc tctcactt 18 <210> SEQ ID NO 28 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 28 tgtaaaacga cggccagt 18 <210> SEQ ID NO 29 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 29 acaaaacgcc tatggtgg 18 <210> SEQ ID NO 30 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 30 ttgatctcag ccctttagc 19 <210> SEQ ID NO 31 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 31 tcatgtggca ggaaactg 18 <210> SEQ ID NO 32 <211> LENGTH: 484 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 32 gcacgagacc agtattacta tacaatgtaa gtgttttaaa aaatacgaaa gtaatactct 60 gcaccccttc ctacaaagat gataaagcag tcacttctgg cgcattttaa taatttaaag 120 atttttagtg caatggcacg gtaacctcca aacctgaatt agacagagac tcactcagga 180 agtgacaggc ccatcatatc aaataactta ttcacttttc atgtggcagg aaactggaat 240 atcgctttta ataaaatgga aaaatatgct tctacatatt taccaccata ggcgttttgt 300 tcatatgagc ctggtttgtg caaaattaaa tcagaggctt ctacacatgg tttatttatg 360 ttgtagcaaa gttggctcta cataaacatt gttcttattt taaaattaac actatgtgtt 420 cgtttttctt gtgggcttct gaaagttgcc atcttccctc cgtggagctc catttgctat 480 tttc 484 <210> SEQ ID NO 33 <211> LENGTH: 404 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 33 cttgaacaca tcatgatata tgcaaaaaat ctagtgaacg ccgaccgctg cgcgctcttc 60 caggtggacc acaagaacaa ggagctgtac tcggacctgt ttgacattgg ggaggagaag 120 gaggggaagc ccgttttcaa gaagaccaag gagatcagat tttccattga gaaagggatt 180 gctggtcaag tggcaagaac gggagaagtc ctgaacattc ctgatgccta cgcagacccg 240 cgctttaaca gggaggtgga cctgtacaca ggctatacca cgcggaacat tctgtgtatg 300 cccatagtga gccgcggcat ttgattcggt gtggtgcaaa tggtttaaca agatcagcgg 360 caggcctttc caagacggat gagaacaact tcaagatgtt ttgc 404 <210> SEQ ID NO 34 <211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:tag <400> SEQUENCE: 34 Asp Lys Asp Asp Asp Asp Lys 1 5 <210> SEQ ID NO 35 <211> LENGTH: 62 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 cagtcagcta gccgccatgg actacaagga cgacgatgac caagttgact gatgaaaagg 60 tg 62 <210> SEQ ID NO 36 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 36 ccagaagggg tacttttcc 19 <210> SEQ ID NO 37 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 37 cattgtcctg aggctgtgg 19 <210> SEQ ID NO 38 <211> LENGTH: 477 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 tatcccaaaa gccgacggat ttgcactgta cttccttgga gagtgcaata atagcctgtg 60 tgtgttcata ccacccggga tgaaggaagg ccaaccccgg ctcatccctg cggggcccat 120 cacccagggt accaccatct ctgcctacgt ggccaagtct aggaagacgt tgttggtaga 180 ggatatcctt ggggatgagc gatttcctcg aggtactggc ctggaatcag gaacccgcat 240 ccagtctgtt ctttgcttgc ccattgtcac tgccattgga gacttgattg gcatccttga 300 actgtacagg cactgggaca aagaggcctt ctgcctcagc catcaggagg ttgcaacagc 360 caatcttgct tgggcttccg tagcaataca ccaggtgcag gtgtgtagag gtctcgccaa 420 acagaccgaa ctgaatgact tcctactcga cgtatcaaag acatactttg ataacat 477 <210> SEQ ID NO 39 <211> LENGTH: 755 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 gaattccttt tgtatttatt tcttctctaa cttactttat ctttttaaat ggaataactc 60 tgatagaatt acagtgttaa tatttgtcta ctttatattt cacactctag aatatattaa 120 atgcttagtc ttttgccgta agatagaaaa agctggttta aaatgagatc cacaagagac 180 cttaccttct gatttgttgt tcttcctctt cagccatttc tctactgtct ctgcactaac 240 actttcagat acaaattcat ctaatacctg ggggtgaaga gaaagatatg ccttcacttt 300 ttcatctgtc aaacctgtaa aagaattgaa aagaataaaa ttcacctata caacatcctc 360 atatcaatga aaggtatagt atcacaacac attatgctaa gacccagcaa cctctcatct 420 aacggagaga gggctggaaa gagcgggaag gggaagctac tgcttagtgg gtacagagtt 480 tctactggga gtgacagcaa agttttggaa ctagacaggt gaatactgcc caacattggg 540 aatatacgta atgccactaa attgtacgct taaaacagca tttaaaatgg taaaaaacac 600 catttttcat atatacgtgt gtgtgtgtgt gtgtgtgtgt atgaccacaa taaaaaagaa 660 tgcagttagt ttagcaattt taaactacat atattacatc atgttacata gctgtttcta 720 gcaataaatt tcagagttac atatgaacca atgcc 755 <210> SEQ ID NO 40 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 40 gttagatgag aggttgctgg 20 <210> SEQ ID NO 41 <211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 41 gtatgctaat ctcag 15 <210> SEQ ID NO 42 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 42 caactcgaat tccttgacag attagcatac 30 <210> SEQ ID NO 43 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 43 caactcgaat tccttgac 18 <210> SEQ ID NO 44 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 44 gttgttcttc ctcttcagcc 20 <210> SEQ ID NO 45 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 45 caactcgaat tccttgacag a 21 <210> SEQ ID NO 46 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 46 gatcgtcgac ctgtctctgc actaacac 28 <210> SEQ ID NO 47 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 47 gatcgtcgac aagcactcgg tcagccttcg 30 <210> SEQ ID NO 48 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence:primer <400> SEQUENCE: 48 gatcggatcc accatggact acaagg 26 

What is claimed is:
 1. A method to identify a specific binding partner of a PDE8 polypeptide comprising the steps of: a) contacting the PDE8 polypeptide with a compound under conditions which permit binding between the compound and the PDE8 polypeptide; b) detecting binding of the compound to the PDE8 polypeptide; and c) identifying the compound as a specific binding partner of the PDE8 polypeptide; said PDE8 polypeptide encoded by a polynucleotide selected from the group consisting of polynucleotides that hybridize under moderately stringent conditions to the complement of a polynucleotide encoding a polypeptide set out in SEQ ID NO: 2, 4, or 6, said moderately stringent conditions comprising a final wash at 65° C. in 2×SSC and 0.1% SDS.
 2. The method according to claim 1 wherein the specific binding partner modulates activity of the PDE8 polypeptide.
 3. The method according to claim 2 wherein the specific binding partner inhibits activity of the PDE8 polypeptide.
 4. The method according to claim 2 wherein the specific binding partner enhances activity of the PDE8 polypeptide. 